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THE ANTITRUST LAWS AND THE HEALTH INDUSTRY
ROBERT P. BORSODY*
T HE HEALTH INDUSTRY is one of the largest and fastest growing sectors
of the nation's economy, yet in the past, trade regulation cases arising
in this area have been disproportionately few. Today this is changing. The
courts and regulatory agencies have increasingly held the attitude that if
physicians and health care providers wish to reap the benefits of commercial
activity they must bear the burden of competition, including trade regulation.
Moreover, many persons in positions of authority believe that restrictive
trade practices such as price fixing agreements and boycotts of health care
providers have caused increases in prices to consumers.' Widespread public
and governmental concern with these rapidly escalating costs2 has caused
federal and state governments to search for methods to contain them. In
addition to the proposals for "cost cap" programs by government and Blue
Cross-Blue Shield and state rate review legislation, the enforcement of
existing antitrust laws has been suggested and is being pursued as a means
of holding down costs.' Such enforcement requires little additional funding
or legislative action, and for this reason too, many antitrust regulators
have announced their determination to initiate aggressive enforcement efforts
in the health care field.'
*Partner, Epstein, Becker, Borsody & Green, New York, New York; Member New York
Bar; LL.B., University of Virginia School of Law.
' A study by the Council on Wage and Price stability concluded that the rise in health care
costs was strongly influenced by lack of vigorous price competition and by restrictions on
advertising. [1967] ANTITRUST & TRADE REG. REP. (BNA) No. 761 at A-18. Similar con-
clusions were reached by Sen. Hart's Subcommittee at hearings held in May of 1974. Hearings
on Competition in the Health Services Market Before the Subcomm. on Antitrust and
Monopolies of the Senate Comm. on the Judiciary, 93d Cong., 2d Sess. (1974).
2 In 1940, health care expenditures were 4.1% of the Nation's Gross National Product. In
1950, they climbed to 4.5% and in 1960 to 5.2%. In 1970, they reached 7.2% and in only
five years the figure rose to 8.3%. Last year in 1977, with the figure at 8.6%, it was esti-
mated that the average American family spent one-twelfth of its budget on health care costs.
Put another way, the typical wage earner works one month out of twelve to pay for health
care. MED. WORLD NEWS, Feb. 21, 1977 at 57. Secretary of HEW, Joseph Califano, Jr.,
testifying before the Senate Finance Subcommittee on Health, on S.1470, a cost containment
bill, said that "the problem of rising costs is of .. . disastrous proportions."
3 Senator Edward M. Kennedy recently made the statement that "health care appears to be
a fertile field for antitrust activity" at the National Leadership Conference on Controlling
Health Care Costs. N.Y. Times, June 28, 1977, at 17, col. 6. The Senator, who then headed
the Senate Health Subcommittee, announced that the Senate Antitrust Subcommittee, which
he also then headed, would hold hearings on anticompetitive practices in the medical and
hospital industries. Id.
'See, e.g., Address by Alfred F. Dougherty, Jr., Director, Bureau of Competition, FTC, and
address by Joe Sims, Deputy Ass't Att'y Gen., Antitrust Div. of the Justice Dept., Nat'l
Health Lawyers Ass'n Seminar in Wash., D.C. (Dec. 12, 1977); Statement by William J.
Brown, Att'y Gen. of Ohio, to the Council on Wage & Price Stability, (Sept. 1976) ("my
[417]
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The health care industry is vast and diverse, ranging from giant
pharmaceutical houses to individual visiting nurses. This article will examine
only the health delivery system and health insurance companies to survey
the present application of the antitrust laws and, when pertinent, to describe
the current status of some of the classical defenses available.
In perusing this survey the reader may well conclude that the health
field has recently been engulfed by litigation. This writer would emphatically
confirm such a conclusion and add that there is more court action to come.
As noted, recent antitrust activity has occurred because of public concern
with apparently restrictive practices in the industry contributing to the
increasing cost of health care. The industry is ripe for regulation. This
regulation will come about primarily through two forms of court action:
(1) private actions initiated by competitors and pursued because of con-
flicting commercial interests, and (2) actions by state and federal agencies.
The number of cases actually litigated by governmental agencies,
however, is very small. This is due primarily to Section 5(a) of the Clayton
Act,5 which permits a private plaintiff to use a criminal conviction or a
civil judgment, obtained by the government after a trial, as prima facie
evidence of a violation of the antitrust laws. Section 5(a) specifically does
not apply to consent decrees entered prior to trial.' Hence, most government
actions are settled by consent decree far in advance of trial. The use of a
judgment in subsequent private actions is thereby avoided.
Section 4 of the Clayton Act7 gives a private party the right to sue
for three times the damage caused to him by activity which violates any
of the federal antitrust laws. The courts term such private parties "indi-
vidual attorneys general," and in this sense these private plaintiffs can,
through the precedential weight of their litigation and through the direct
effect of injunctions they may secure, influence the practices of an entire
industry. The major part of this article will examine these private antitrust
actions.
I. THE ANTITRUST LAWS AND THE ENFORCEMENT AGENCIES
A. Federal Legislation
Before discussing the case law, it may be helpful to outline the major
remarks will focus on the need for vigorous antitrust enforcement and increased competition
in the health care industry, which I believe, could save consumers literally billions of dollars
yearly.") See generally Trustbusters Push Into Medical Picture, MED. WORLD NEWS, Oc-
tober 17, 1977, at 50.
5Clayton Act, § 5(a), 15 U.S.C. § 16(a) (1976).
6 Id. See Annot., 10 A.L.R. FED. 328 (1972). A consent decree is an agreement by the de-
fendant to discontinue the challenged trade practice without admitting wrongdoing.
7 Clayton Act § 4, 15 U.S.C. § 15 (1976).
[Vol. 12:3
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federal antitrust statutes and to describe the administrative agencies charged
with the enforcement of governmental policy through these laws.
The first of the American antitrust laws is the Sherman Antitrust Act,
enacted in 1890. 8 Section 1 of this statute prohibits contracts, combinations,
and conspiracies in restraint of trade or commerce.' This includes all forms
of agreements to fix prices and to allocate territorial markets. Most of the
private litigants in the health care industry to date have alleged a violation
of Section 1 of the Sherman Act. Section 2 of the Act makes it illegal to
monopolize, to conspire to monopolize, or to attempt to monopolize.10
Significantly, an increasing number of private antitrust actions in the health
field are premised, at least in part, on alleged violations of Section 2.
The Clayton Antitrust Act contains other legislative provisions" which
may become more familiar to health care providers, but which have as yet
been sparingly invoked. Section 3 of this Act deals with "tie-in" sales agree-
ments.12 A "tie-in" is a condition which requires that a purchaser buy one
product in order to obtain a second. The sale of the first product is thus
"tied" to the sale of the second, since the purchaser can obtain the second
product only through the purchase of the first. Such an arrangement violates
Section 3 only when no comparable substitute for the desired second
product is available to the purchaser, 1 and he is thus compelled to purchase
the tied product. This showing of monopoly power is the crucial element
of a Section 3 violation. For example, the only hospital in a town might
require a patient to purchase drugs or prosthetic devices as a precondition
to becoming or remaining a patient.
In medicine, quality control considerations often justify certain tie-in
arrangements. Thus, a hospital may rightfully require certain minimum
quality standards for prosthetic devices used on its premises as a reasonable
safeguard consistent with patient safety and risk management programs.
If the standards are such that only devices furnished by the hospital comply,
however, the hospital could be in violation of Section 3. An illustration
from industry is relevant: American Telephone and Telegraph (AT&T)
for many years required that subscribers use only instruments furnished by
the company in order to avoid possible damage to the network of switching
and transmission equipment it maintained. With some prompting from
8 15 U.S.C. §§ 1-7 (1976).
9 Id. at § 1.
'Old. at § 2.
11Id. at §§ 12, 13, 14-22, 23-27; 29 U.S.C. §§ 52, 53 (1970).
12 15 U.S.C. § 14 (1976).
2' Thus, the Sherman Act can also be used to support a tie-in case. In the health care field
this would be the usual approach since the Clayton Act covers trade involving the sale of
goods and not the provision of services.
Winter, 1979]
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private litigants and regulatory agencies, AT&T has dropped this require-
ment and now permits the use of other electronically compatible equipment.
Hospitals are in a similar situation. Before they rely on a "quality assurance"
argument in tying products to services, cognizance should be taken of the
dangers involved as evidenced by the AT&T example.
The third major relevant statute is the Federal Trade Commission
Act." Section 5 of this act prohibits a broad variety of "unfair methods, of
competition."' 5 For example, a hospital might drive a clinic out of business
by establishing a competing clinic across the street and attracting the com-
petitor's patients with a schedule of lower-than-cost charges. The hospital's
other operations could subsidize the operation of its money-losing clinic
until the competitor is driven out of business. At that point, the new clinic
would raise its prices to a level exceeding the former competitor's original
prices. The original clinic having been driven out of business, the public
is thus faced with a monopoly, and is forced to pay the inflated monopoly
prices.
This scheme has been used many times in mercantile or industrial
enterprises but is not so readily adaptable to the health industry. Many
unique characteristics distinguish the health industry from its mercantile
or industrial counterparts. Some of these salient characteristics are con-
sumer ignorance concerning the comparative quality of health services, a
prevalent perception of medical services as being personal and unique and
not comparable on the basis of price alone, ignorance of price and avail-
ability of health services due to advertising constraints, consumer insensi-
tivity to cost considerations due to widespread third party reimbursement,
and the consumer's unfamiliarity with the system due to the often episodic
or emergent access to it.
Thus, in order to be effective in the health field, this particular scheme
of predatory pricing would certainly require advertising, which to date has
not been used. Even then, with third party coverage for most patients,
the pricing scheme would possibly not be as effective as it has been in other
areas of commerce and industry. However, with the current trend toward
the approval of advertising which we have seen in some states (Arizona,
for example) it may well be that the health industry will become somewhat
more vulnerable to such predatory pricing tactics in the future.
Mergers with anticompetitive effects are barred by Section 7 of the
Clayton Act." In the health industry, this Section would most likely be
14 15 U.S.C. §§ 41-46, 47-58 (1970).
15 Id. at § 45 (1976).
16Id.. at § 1.
[Vol. 12:3
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applied to a merger of competing hospitals. It could conceivably be applied
to the acquisition of an additional institution by one of the religious orders or
large foundations which already operate a number of such institutions.
However, Section 7 cases are rare in the health industry, primarily because
the industry is so fragmented.
The antitrust offense occurring most frequently in the health field is
the group boycott or concerted refusal to deal. Illegal under both the Sherman
Act and the Clayton Act, depending on its factual background, it could
occur in a number of circumstances in the health industry. Providers who
agree to shun a third party reimbursement source, often for the purpose
of inducing higher fees; insurers who refuse to include coverage for the
services of a particular provider group; or physicians who boycott a hos-
pital in a board-medical staff dispute, can run afoul of this antitrust
principle. The essence of this offense is the agreement or conspiracy not to
deal with the excluded group or entity. Individual providers, on the other
hand, remain free to choose with whom they will do business, at least as
far as the antitrust laws are concerned.
Most states have comparable antitrust statutes and regulations, although
the degree to which they are enforced varies from state to state.1" The
Attorney General of Ohio has proclaimed a vigorous campaign to use the
state and federal antitrust laws to attempt to lower the cost of health care
to Ohio citizens."8 Actions taken so far in Ohio include a suit against the
state medical society and the Blue Shield plan of the state under sections
1 and 2 of the Sherman Act and Section 7 of the Clayton Act,"9 and two
antiboycott cases: one against a county medical society for attempting to
prevent doctors from working for a health maintenance organization,"°
and another against dentists for refusing to treat Medicaid patients until the
rates were raised.2 '
The Hart-Scott-Rodino bill, entitled the Antitrust Improvements Act
of 1976, added a provision allowing state attorney generals to bring private
treble damage actions on behalf of the citizens of their states. The Tunney
Amendments, entitled the Antitrust Penalties & Procedures Act of 1974,
changed violations of the federal antitrust laws from misdemeanors to
felonies and increased the maximum penalties to three years imprisonment
and fines of $100,000 for individuals and $1,000,000 for corporate offend-
'1 A compilation of state antitrust laws can be found in 4 TRADE REG. REP. (CCH) 30,000.
is See note 4 supra.
19 See note 143 infra; notes 203-205 and accompanying text infra.
20 See note 158 and accompanying text infra.
21 See note 169 and accompanying text inira.
22 15 U.S.C. § 15(c)-(h) (Supp. 1977).
Winter, 19791
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ers." With these kinds of penalties, health providers are well advised to
carefully consider the antitrust consequences of any planned activity which
has significant economic or competitive impact.
B. Enforcement
As mentioned before, most of the antitrust case law derives from dis-
putes between private parties. Criminal proceedings under the federal anti-
trust laws are the province of the United States Department of Justice.
These actions are usually reserved for blatant offenses in the clearly defined
areas of the law. Businessmen know they should not fix prices. If they are
challenged by the Antitrust Division of the Justice Department, courts
and juries have little sympathy for them. In the health field the guidelines
are far less clear. Strong health policy arguments based on considerations
of quality and ethics support what in another industry would be clearly
labelled price fixing."' Until civil cases and perhaps additional legislation
clarify the gray areas of antitrust policy in the health industry, it is very
unlikely there will be any criminal actions brought by the Justice Depart-
ment.
Civil enforcement of the antitrust laws is the responsibility of both
the Antitrust Division of the Justice Department and the Federal Trade
Commission (FTC). The Clayton Act gives both agencies responsibility
for enforcement of Sections 2, 3, 7 and 8.25 Although the Sherman Act
gives authority for enforcement only to the U.S. Attorney General, "6 the
Supreme Court has held that restraints of trade in violation of the Sherman
Act may also be found to be unfair methods of competition under Section
5 of the Federal Trade Commission Act.27
The Federal Trade Commission is an independent regulatory body
which was created in 1914 under the FTC Act.28 The responsibilities of
the FTC extend beyond antitrust enforcement; it also has the power
to enforce a variety of consumer protection statutes. The FTC's Bureau
of Competition is concerned with preserving competition by enforcing Sec-
23 15 U.S.C. § 1-3 (Supp. 1977). Cases involving price discrimination under the Robinson-
Patman Price Discrimination Act, id. at H9 13, 13a, 13b, 21 (1976), are rare in the health
field. Although there are a number of such cases involving the drug companies, only one has
been found in the health care delivery sector. Abbot Labs., Inc. v. Portland Retail Druggists
Ass'n, Inc., 425 U.S. 1 (1976).
24 The exact definition of price fixing as it occurs in the health industry is a problem which
will be discussed later in connection with relative value scales. See text accompanying notes
173-77, infra.
25 15 U.S.C. § 21, 25 (1976).
26 Id. at § 4.
27 Federal Trade Comm'n v. Cement Inst., 333 U.S. 683, 693 (1948); Federal Trade Comm'n
v. Beech-Nut Packing Co., 257 U.S. 441, 453-54 (1922).
" 15 U.S.C. § 41-77 (1976).
[Vol. 12:3
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tion 5 of the FTC Act. In this enforcement the Bureau has great flexibility.
It can conduct investigations, bring administrative proceedings before the
Commission, or appear in court to conduct its own litigation. Penalties
include heavy fines and injunctions. Cases can also be referred to the
Department of Justice for prosecution.
Task force groups in both the FTC and the Justice Department's
Antitrust Division have been investigating the need for enforcement and,
when the decision is made to proceed, compiling evidence for prosecution
of an action in the health area. Consequently, we may expect a series of
enforcement proceedings in the next few years. The current activities of the
task forces will be discussed further in this article.
II. THE LAWS INTERPRETED: THE CASE LAW
As an introduction to the cases interpreting the statutes outlined above,
the defenses most frequently raised to actions under those statutes will be
discussed. This discussion will review most of the earlier cases in which
these defenses were raised, often with great success. In recent times, they
have more frequently been brushed aside by the courts.
A. Defenses
1. The Professional Exemption and the Effect on Interstate Commerce
The first cases to be considered deal with two defenses which are
often raised together. The first, the interstate commerce defense, derives
from the requirement of the federal laws that the illegal activity affect inter-
state commerce. The defendant in this instance argues that restraint of
plaintiff's commerce does not substantially affect interstate commerce.2" The
second defense, the professional exemption, stems from the fact that the
antitrust laws apply only to a trade or business. Until recently, this re-
quirement had been thought to exempt the learned professions from their
scope. In raising this defense the defendant claims that the economic ac-
tivity said to be restrained is in fact not a "business" but rather a profession
and so exempt from the antitrust laws. Both defenses are usually raised
by motion in advance of trial and must be considered and resolved in plain-
tiff's favor before a court can go on to deal with the merits of the action.
The interstate commerce defense is treated in various ways, depending
upon the parties to the action and the allegations in the complaint. In cases
where hospitals or other health institutions, as plaintiffs, claim the restraint,
the defense has not often been successful. When an individual medical
29These requirements of the federal laws are referred to in the shorthand of the legal pro-
fession as follows: The first requires that the offense be "in commerce" and the second, that
it "affect trade or commerce."
Winter, 19791
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practitioner claims a restraint, the defense has been more successful. De-
fendants in the first type of case often support this defense with the argument
that hospital activities are strictly local in nature and do not constitute inter-
state commerce. However, in antitrust litigation the courts have generally
held that once an offense is present, a surprisingly small effect on inter-
state commerce justifies a finding of federal jurisdiction."° Hospitals, as
administrators know, acquire supplies and products from interstate sellers
which represent a significant expenditure. This, plus the care of patients
from out of state, would be enough under recent case law to produce the
necessary effect on interstate commerce.
Three leading cases have illustrated that courts are not likely to dis-
miss an action by an institutional plaintiff on the basis of the interstate
commerce defense. The most recent case affirming the principle that restraint
of the hospital business can affect interstate commerce is Hospital Building
Co. v. Trustees of the Rex Hospital."1 In Rex, the petitioner, a small propri-
etary hospital, charged that respondents conspired to monopolize the hos-
pital business in the community and to prevent petitioner's expansion by
opposing plaintiff's application for a certificate of need. Defendants in the
action were a voluntary hospital, its administrator, one of its trustees, and
an official of the local health planning agency. The Supreme Court reversed
the lower courts' failure to find the requisite effect on interstate commerce,
holding:
Petitioner's purchases of out-of-State medicines and supplies as
well as its revenues from out-of-State insurance companies would be
thousands and perhaps hundreds of thousands of dollars less than
they would otherwise be. Similarly, the management fees that peti-
tioner pays to its out-of-State parent corporation would be less if the
expansion were blocked. Moreover, the multimillion dollar financing
for the expansion, a large portion of which would be from out of State,
would simply not take place if the respondents succeeded in their
alleged scheme. This combination of factors is certainly sufficient to
establish a "substantial effect" on interstate commerce under the Act. 2
Further the court noted that the plaintiff hospital served out-of-state pa-
tients."3
30 Although the statute requires a substantial effect on interstate commerce, if the offense
is clear, the Supreme Court has sanctioned attack on local restraint when important in the
local area even in the absence of such substantial effect. See Mandeville Island Farms, Inc.
v. American Crystal Sugar Co., 334 U.S. 219 (1948); United States v. Employing Lathers
Ass'n of Chicago, 347 U.S. 198 (1954).
31425 U.S. 738 (1976).
S2 Id. at 744.
331d. at 741.
[Vol. 12:3
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Similarly, in Doctors, Inc. v. Blue Cross of Greater Philadelphia,3" a
Philadelphia proprietary hospital claimed that Blue Cross was monopolizing
the business of financing health care in the city. The defendant's motion
to dismiss on the basis of an insubstantial effect on interstate commerce
was denied, the court finding that approximately $23 million in medical
supplies were being shipped into the state annually.35 However, this case
was later dismissed on the basis of another defense, the exemption of the
insurance industry from the antitrust laws,36 which will be discussed herein."
The third case, St. Bernard General Hospital, Inc. v. Hospital Service
Association of New Orleans, Inc.,8 was brought by a group of proprietary
hospitals claiming a boycott by defendants, the Blue Cross Association
and its member hospitals. The trial court dismissed the action on the basis
that hospital services are local in character and do not affect interstate
commerce. On appeal the Fifth Circuit Court of Appeals reversed.
There remains little doubt at this point that reliance can no longer be
placed upon those older cases with holdings similar to the district court's
ruling in St. Bernard. Rare indeed would be the hospital today whose ac-
tivities would not have an effect on interstate commerce sufficient to sustain
antitrust jurisdiction.
The interstate commerce defense has, however, been sustained in
cases involving suits by single practitioners since their effect on interstate
commerce will most likely be small in comparison to hospitals. In Riggall
v. Washington County Medical Society,3" for example, the plaintiff physician
brought an action under the Sherman Act, charging that he was wrongfully
excluded from the defendant medical society. The court dismissed the
action, upholding the interstate commerce defense. Passing on this juris-
dictional issue, the court said:
There is no allegation in the complaint remotely suggesting that the
acts of the defendants cast any burden upon interstate commerce. The
mere fact that plaintiff at his location in Arkansas may be treating
patients from other states who must travel interstate does not result
in practicing his profession in interstate commerce as the transportation
of such patients is incidental. "°
The Riggall court then went on to describe and quote from a previous
a4 490 F.2d 48 (3d Cir. 1973).
35 1 d. at 51.
56 431 F. Supp. (E.D. Pa. 1975), af'd per curiam, 557 F.2d 1001 (3d Cir. 1976).
37 See text accompanying notes 112-143 infra.
38510 F.2d 1121 (5th Cir. 1975).
30249 F.2d 266 (8th Cir. 1957), cert. denied, 355 U.S. 954 (1958).
40 249 F.2d at 268.
Winter, 1979]
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case in which the defense was successfully asserted against a claim brought
by a small hospital:
In Spears Free Clinic Hospital for Poor Children v. Cleeres, ... [197 F.2d
125 (10th Cir. 1952)], action was brought against the Medical So-
ciety of Denver City and County, former and present members of
the State Board of Health and former and present officials and trus-
tees of the Medical Society based on alleged violations of Sections 1
and 2 of the Sherman Anti-Trust Act. There it was alleged that
"numerous persons from all of the United States, and from many
foreign countries" regularly came to the plaintiff institution for treat-
ment .... Referring to these charges the court among other things said:
The practice of the healing arts in Colorado, including chiro-
practic, is wholly local in character. The alleged conspiracy and
the acts alleged to have been done in furtherance thereof had
for their purpose and object the monopolization and restraint of
purely local activities. No price fixing or price maintenance for
professional or other services was involved. There was no intent
to injure, obstruct or restrain interstate or foreign commerce.
The mere fact that a fortuitous and incidental effect of such con-
spiracy and acts may be to reduce the number of persons who
will come from other states and counties to the Spears Hospital
for chiropractic treatments does not create such a relation be-
tween interstate and foreign commerce and such local activities
as to make them a part of such commerce. "
Neither Riggall nor Spears is a recent case, being twenty and twenty-
five years old, respectively. Indeed, the reasoning in Spears on the nature
of interstate commerce was attacked as being outmoded in United States
Dental Institute v. American Association of Orthodontists."2 However, in
Dental Institute, the volume and type of business involved was quite different
from that in Spears. Dental Institute involved a private dental school alleging
antitrust violations by an orthodontist association. There was a substantial
effect on interstate commerce due to large purchases of out-of-state ortho-
dontic supplies."3 Indeed, in the Dental Institute case, Spears and other
cases were distinguished on just that basis, the district court stating
that they were: "cases in which the courts held that the rendering of medical
services by a single hospital or a single physician, in a single state, was
41 Id. at 270. See also Elizabeth Hosp., Inc. v. Richardson, 269 F.2d 167 (8th Cir. 1959),
cert. denied, 361 U.S. 884 (1959) (related case, same holding); Robinson v. Lull, 145 F.
Supp. 134 (N.D. Ill. 1956) (Doctor excluded from medical society. Following Spears, the
court found no effect on interstate commerce).
42396 F. Supp. 565 (N.D. 111. 1975).
*3 Id. at 578.
[Vol. 12:3
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essentially local in character, despite the fact that some patients came from
outside the state for treatment.""'
Moreover, in a more recent case involving medical staff privileges, the
Tenth Circuit Court of Appeals firmly held that the individual practice of
medicine was intrastate in character. Reliance was placed on Spears and
Riggall as precedent. In this case, Wolf v. Jane Phillips Episcopal-Memorial
Medical Center,5 an osteopathic physician claimed an exclusionary boycott
under Section 1 of the Sherman Act against two hospitals. The circuit court
affirmed the district court's dismissal of the action for failure to establish
a substantial effect on interstate commerce. The court conceded that there
was an offense, saying: "The effect of the alleged conspiracy is clearly to
restrain the plaintiff from practicing medicine and furnishing medical services
as a member of the defendants' medical staff. The question arises, then,
whether the defendants' conduct has substantially affected interstate com-
merce.""6
After reviewing the facts of both Spears and Riggall, the court con-
cluded: "We reach the same conclusion in the case at bar; the facts alleged
do not support the proposition that the restraint upon plaintiff's practice
causes more than an insubstantial effect upon interstate commerce. 4 7
The court added a footnote which specifically narrowed the holding
to individual practitioners:
Although we recognize that cases such as Oregon State Medical Society
and Spears could be read as suggesting the proposition that state-wide
professional organizations and their members do not engage in interstate
commerce in any of their activities - or, at any rate, that they are
somehow effectively exempt from the antitrust laws, we do not sub-
scribe to that proposition in support of our decision in the instant case.
We have referred to those cases, rather, for the more narrow propo-
sitions, that the plaintiff's business of practicing medicine and furnishing
medical services is wholly intrastate in character. 8
It should be made clear that the interstate commercial activity which
forms the jurisdictional basis for an antitrust action must be entirely that
of the plaintiff and not of the defendants'. This was explained in the Wolf
case as follows:
Plaintiff also seeks to establish jurisdiction by focusing upon the inter-
state nature of the defendants' business of providing hospital care
44Id.
45513 F.2d 684 (10th Cir. 1975).
-Id. at 686.
47 ld. at 687.
4"Id. at 687 n.1.
Winter, 1979]
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services. Thus, relying on Doctors, Inc. v. Blue Cross of Greater Phila-
delphia, . . . he contends that jurisdiction is present in the instant
case.... We note first, that, aside from a general allegation that his
business involves interstate commerce, the plaintiff does not suggest
that the defendants' conspiracy threatens his purchase of interstate
goods or that the flow of such goods would be affected in any way
by his exclusion from the defendants' medical staff....
Second, we note that the plaintiff, by his general allegation that the
defendants' business involves interstate commerce, has suggested that
that business has been affected by the defendants' conspiracy to exclude
plaintiff from their medical staff. Nonetheless, even were we to con-
cede, by Doctors, the interstate character of defendants' business, we
fail to perceive the relevance to the plaintiff's claim that the defendants
adopted a plan, that the plan limited or controlled the membership of
the defendants' own medical staff, and that the plan in a very con-
ceptual sense thereby affected the services which the defendants them-
selves might provide. The facts alleged by the plaintiff cannot support
the proposition that his exclusion from the medical staff has affected,
or threatens to affect, the defendants, their hospitals, or through them
interstate commerce. The facts do not support the existence of the
requisite nexus between the defendants' conduct and the interstate
commerce.
4 9
No case has been reported in which an individual practitioner of
medicine was sued and raised the defense that any restraint caused by his
actions did not affect interstate commerce. In such a case the standards
applied by a court might well differ from those used in cases like Wolf
and Riggall, in which an individual practitioner sued and the defendants
showed that any restraint of plaintiffs practice failed to affect interstate
commerce.
These examples suggest that the defense of an insubstantial effect
on interstate commerce is indeed an uncertain assertion for a defendant
to rely upon in an era of rapid communication, mobile population, and
pervasive governmental regulation and financing of the health care industry.
The case of Zamiri v. William Beaumont Hospital,"0 may presage the future
status of this defense in the courts. In Zamiri, the plaintiff claimed that he
was the victim of a boycott when he was denied hospital privileges. The
491d. at 687-88. Accord American Medical Ass'n v. United States, 317 U.S. 519, 528-29
(1943); Friends of Animals, Inc. v. American Veterinary Medical Ass'n, 310 F. Supp.
1016, 1017 (S.D.N.Y. 1970).
50430 F. Supp. 875 (E.D. Mich. 1977). In an even more recent case where a physician
claimed a boycott by a hospital, the court dismissed following Wolf v. Jane Phillips Epis-
copal-Memorial Hospital, although the plaintiff sought to rely on Hospital Building Co. v.
Trustees of the Rex Hospital. Crane v. Intermountain Health Care, Inc. No. C 77-0113
(D. Utah March 17, 1978). It did not appear, however, that the plaintiff had alleged loss
of Medicare and Medicaid funds as had been done in Zarniri v. William Beaumont Hospital.
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court refused to dismiss the action on the grounds of failure to affect inter-
state commerce because the plaintiff physician alleged that defendant's re-
straint of his practice caused him to lose Medicare and Medicaid funds.
The court distinguished this case from Wolf v. Jane Phillips Episcopal-
Memorial Hospital, a case with quite similar facts, solely on the ground
that there had been no allegation in Wolf that Medicare and Medicaid funds
were affected."
The exemption of learned professionals from the antitrust laws is
closely allied to and often argued simultaneously with the interstate com-
merce defense. In both instances, the defendant argues that the activity
allegedly restrained does not constitute "trade or commerce" which affects
interstate commerce. While the professional exemption has never been
applied to a hospital, it has been successfully argued in a number of cases
involving practicing physicians. When dealing with the professions the
courts have generally applied different and less strict rules than in com-
mercial cases. This principle is stated in Jones v. N.C.A.A.: "The prescrip-
tions of the [Sherman] Act were tailored for the business world, not as a
mechanism for the resolution of controversies in the liberal arts or in the
learned professions.' ' 52
An early case, decided in 1931, Federal Trade Commission v. Raladam
Co.,"5 exempted the medical profession from trade regulation. In Raladam
the Supreme Court indicated that "medical practitioners . . . follow a pro-
fession and not a trade."'
Perhaps the leading case establishing this exemption is United States
v. Oregon State Medical Society,55 which squarely held that the "sale of
medical services ...within the State of Oregon is not trade or commerce
within the meaning of Section One of the Sherman Antitrust Act. '56 The
Supreme Court went on to observe that:
there are ethical considerations where the historic direct relationship
between patient and physician is involved which are quite different
from the usual considerations prevailing in ordinary commercial mat-
ters. This Court has recognized that forms of competition usual in
5 430 F. Supp. at 876 n.4. See also Haddy v. Grass Valley Medical Quality Ass'n, No. S-77
-461 TJU (E.D. Cal. Feb. 28, 1978) (where the interstate commerce defense was denied
when plaintiffs alleged a boycott resulting from the requirement that all patients consent to
binding arbitration for medical malpractice claims.)
52 392 F. Supp. 295, 303 (D. Mass. 1975). See Grad, The Antitrust Laws and Professional
Discipline in Medicine, 1978 DUKE L.J. 443 (1978).
53283 U.S. 643 (1931).
"id. at 653.
55 343 U.S. 326 (1952).
66d. at 338.
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the business world may be demoralizing to the ethical standards of
a profession. Semler v. Oregon State Board of Dental Examiners, 294
U.S. 608. 57
This principle was reaffirmed, the Oregon State Medical Society
case cited and the above passage quoted in the landmark case which
has gravely challenged the application of the professional exemption to
all professions, Goldfarb v. Virginia State Bar.8 In Goldfarb, the plaintiff
was unable to find a lawyer to represent him in the purchase of a home
who would charge less than the one percent minimum fee contained in the
fee schedule of the local county bar association. This prospective home buyer,
an attorney with the Federal Trade Commission, felt this fee schedule
constituted price fixing. The Supreme Court agreed. The Court found that
the facts showed a:
fixed rigid price floor . . . [of] minimum fees to be charged in future
transactions, and those minimum rates were increased over time. The
fee schedule was enforced through the prospect of professional dis-
cipline from the State Bar.... [T]he motivation to conform was re-
inforced by the assurance that other lawyers would not compete by
underbidding.... [H]ere a naked agreement was clearly shown, and
the effect on prices is plain .... Respondents' activities constitute a
classic illustration of price fixing."
The Court struck down the learned profession defense, finding no
basis for it in federal legislation and saying: "The nature of an occu-
pation, standing alone, does not provide sanctuary from the Sherman Act...
nor is the public service aspect of professional practice controlling in de-
termining whether Section 1 includes professions. '""°
However, the Court made an important qualification of this holding in
footnote seventeen:
The fact that a restraint operates upon a profession as distinguished
from a business is, of course, relevant in determining whether that
particular restraint violates the Sherman Act. It would be unrealistic
to view the practice of professions as interchangeable with other business
activities, and automatically to apply to the professions antitrust con-
cepts which originated in other areas. The public service aspect, and
other features of the professions, may require that a particular practice,
which could properly be viewed as a violation of the Sherman Act in
67 Id. at 336 citing Semler v. Oregon, 294 U.S. 608 (1935).
58421 U.S. 773 (1975).
59 1d. at 781-83.
60 ld. at 787.
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another context, be treated differently. We intimate no view of any
other situation than the one with which we are confronted today.61
Most courts considering the professional exemption defense after
Goldfarb have concluded that professionals are no longer exempt from anti-
trust allegations." This was certainly the case in Ballard v. Blue Shield of
Southern West Virginia, Inc.," a suit brought against the state's Blue Cross-
Blue Shield insurers by a group of chiropractors claiming that the defen-
dants boycotted them by refusing to provide coverage for chiropractic
services. The court, relying on Goldfarb, denied a motion raising the pro-
fessional exemption defense."4 The court also denied the interstate com-
merce and insurance exception defenses raised in the same motion.6"
Veizaga v. National Board for Respiratory Therapy exhibits a more
carefully reasoned approach to the current applicability of the professional
exemption after Goldfarb.6" In its opinion the court dealt with the suggestion
in footnote seventeen of Goldfarb and concluded:
Where professional organizations are alleged to have committed a
per se offense, a two-step analysis is required. First, the court must
determine whether the challenged activity is, by its nature and character,
commercial. If the Court should find that it is commercial, the pro-
fessional organization may be liable for a per se offense. However, if
the court should find the activity to be noncommercial, it should then
apply a rule of reason analysis, using the factors outlined in Board of
Trade v. United States ..... We believe that the second step is neces-
sary to ensure that those professional activities, while noncommercial
in their character, but unreasonable (in the antitrust sense) in their
impact, are subject to the antitrust laws. This analysis satisfies the
concern of the Court that professions should be subject to the antitrust
laws but still be treated differently where the public service aspects of
the profession are involved." '
6 ld. at 787 n.17.
62 The antitrust enforcers took a similar position. In a speech shortly after the Goldfarb
decision, a representative of the Antitrust Division said:
The Supreme Court's clear unequivocal, and unanimous rejection of any idea that the
learned professions are exempt from the antitrust laws is a clear signal to all professions.
In the unlikely event that the signal is not clear, let me state that we regard the demise
of the "learned profession" exemption as complete.
Address by Thomas E. Kauper, Ass't Att'y Gen., Antitrust Division, Oregon Bar Conference
on Federal and State Antitrust Enforcement, Portland, Oregon (October 24, 1975).
63543 F.2d 1075 (4th Cir. 1976).
641d. at 1079.
65 Id. at 1078.
66 1977-1 TRADE CASES (CCH) 1 61,274 (N.D. Ill. Jan. 27, 1977). The court recently denied
a subsequent defense motion for summary judgment. 1979-1 TRADE CASES (CCH) 62,496
(N.D. Ill. Feb. 13, 1979).
6 1d. at 70,870.
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A per se offense, referred to by the court, is one which the courts have
found to be by its very nature illegal under the antitrust laws."3 No showing
of anticompetitive effect is necessary. Price fixing, tie-in agreements, and
boycotts are examples of per se offenses. The rule of reason analysis, which
applies in the absence of a per se offense, requires a showing of substantial
adverse effect on competition within the industry. A sound business reason
can, under the rule of reason, serve to justify the challenged practice if the
reason is unrelated to anticompetitive purposes.
Another court has used a two-step approach, slightly different from the
one in the Veizaga case, in a recent post-Goldfarb case, Feminist Women's
Health Center, Inc. v Mohammad.9 In that case the court denied a pre-
liminary injunction for lack of a showing of irreparable harm to plaintiffs.
The court, however, analyzed the merits, noting that there existed a "sub-
stantial likelihood of success on the merits" regarding an alleged boycott
of an abortion clinic by the defendant doctors and medical society."0 While
this would otherwise be a per se violation of the Sherman Act, the court
noted:
[T]his case presents the problem of applying these historic antitrust
doctrines in the area of a profession which is highly regulated by the
state, and intimately concerns the public health and welfare. In its
recent opinion of Goldfarb v. Virginia State Bar, . . . the Supreme
Court intimated that due deference to the state's interest in controlling
and regulating the professions must be given by the federal courts in
applying the antitrust laws. Therefore, in the professional context the
application of the historic antitrust doctrines may be somewhat different
from the application of those doctrines in purely commercial settings.
In other words, the professions are a special case under the antitrust
regulating scheme, and the impact of state regulation and policy
must be measured in any action against members of such profession.
The question therefore arises whether the per se doctrine may be ap-
plied at all in an antitrust case brought against members of the medical
profession and, if so, to what extent? In the court's view, the per se
doctrine does have application in this case, although it must be harmo-
68 The courts define per se offenses as those which: "[b]ecause of their pernicious effect on
competition and lack of any redeeming virtue are conclusively presumed to be unreasonable
and therefore illegal without elaborate inquiry as to the precise harm they have caused or
the business excuse for their use." Northern Pacific Ry. Co. v. United States, 356 U.S. 1, 5
(1958). See generally 16 VON KALINoWsri BUSINESS ORGANIZATIONS: ANTITRUST LAWS AND
TRADE REGULATION § 6.02(3a-f) (1978).
69 415 F. Supp. 1258 (N.D. Fla. 1976). This case was later dismissed on a motion for sum-
mary judgment by defendant doctors which was reversed on appeal, the Fifth Circuit agree-
ing with much of the District Court opinion discussed in the text. 586 F.2d 530 (1978).
70 Id. at 1270.
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nized with the pecularities of the profession involved and the dictates
of state policy regarding the profession."'
The court concluded that, because of the state's authorization to the
medical profession to organize themselves, " "good intentions would be a
defense to a per se violation." 3 The court described the distribution of the
burden of proof in the case as follows:
Plaintiff, of course, carries the burden of proving jurisdiction under
the Sherman Act. In addition, plaintiff must establish a case showing
a combination or conspiracy in the nature of a boycott, and that such
combination or conspiracy resulted in the interference with and damage
to plaintiff's business. But plaintiff need not prove that the restraint of
trade occasioned by the combination or conspiracy was unreasonable,
and that the conspirators had specific intent to violate the antitrust
laws, nor that public harm ensued from the actions of the combinations.
To this extent the application of the per se doctrine in this case is facile.
If plaintiff establishes the elements outlined above, defendants must
bear the burden of proof on the "good faith" defense.'
The defense of good faith was explained by the court to require that
defendants show that:
their action was motivated by a bona fide concern over the existence
of satisfactory medical care rather than by concern over the economic
impact of competition upon their medical practices. For only if they
were motivated by such bona fides can their actions be deemed reason-
able under the per se doctrine, if plaintiff has established a prima facie
per se case. 5
In Feminist the court indicated that the defendants may not be able
to sustain their burden of proof since "the mainspring of defendants' action
was economic. '0 In particular, a principal doctor defendant was shown
to have voiced concern for the adverse effect on his own practice of the
competition of plaintiff. 7' Hence, notwithstanding their claims of public in-
terest and concern for patient care, the court was of the opinion that the
plaintiff could show at trial that the defendants were engaged in a restraint
71 Id. at 1262-63.
72 The court states at 1263 that FLA. STAT. § 768.131 (1975), authorizes the medical pro-
fession to organize.
"3Id.
74 Id.
75 1d.
76 Id. at 1270.
77 Id. at 1269.
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of trade no different than that of a commercial interest which conspires to
put a lower priced competitor out of business."8
In both Goldfarb and Feminist, a determinative factor in the finding
of an offense was a showing of defendants' obvious attempts to gain eco-
nomic advantage by the use of a blatant anticompetitive device. In the
first case, establishing fees at a certain minimum level fixed prices."' In the
second, a group boycott attempted to drive a lower priced competitor out
of business. A similar showing in any future antitrust case is sure to preclude
serious consideration of the professional exemption defense.
The Veizaga and Feminist cases, however, differ significantly in their
interpretation and application of the defense. In Feminist, proof of "good
faith" by a professional would have been a solid defense against allegations
of a per se offense. This good faith showing requires establishing a sound
business reason under the rule of reason analysis. In Veizaga on the other
hand, if a per se offense were shown, there would have to be a finding that
the activity is "noncommercial" before the rule of reason analysis could
apply. Presumably, good faith would then be a defense under the rule of
reason analysis. However, if there is a finding that the challenged activity
is commercial by virtue of the Veizaga interpretation, no rule of reason
analysis and no good faith showing would be allowed the professional
defendant.
The view utilized by Feminist is more liberal because it implies that
professionals can defeat any per se charge by a showing of good faith. In
contrast, the Veizaga view requires that the activity first be found non-
commercial before the showing of good faith can be made. Even the inter-
pretation used in Veizaga, however, gives the professional the advantage of
being able to demonstrate that the challenged activity is not commercial.
Good faith would then be a complete defense.
In conclusion, professional persons and their organized activities con-
tinue to be in a somewhat favored position, although since Goldfarb the
circumstances in which the defense can be successfully asserted have been
significantly circumscribed. The success of the argument may well depend
to some degree on the particular court deciding the issue as well as whether
I8 Id.
79 In the Goldfarb case, the Supreme Court punctured the public interest protestations of the
defendants with the following footnote: "The reason for adopting the fee schedule does not
appear to have been wholly altruistic. The first sentence in respondent State Bar's 1962
Minimum Fee Schedule Report states: The Lawyers have slowly, but surely, been committing
economic suicide as a profession.'" 421 U.S. at 786 n.16.
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the action is predicated upon federal or state statute. 0 One thing is for sure,
professionals can no longer ignore antitrust legislation with impunity.
2. The State Action Defense: Parker v. Brown
The state action defense is based on the premise that if the antitrust
laws are intended to protect the public by preserving competition, which
ensures low prices and high quality, they are not necessary in those highly
regulated markets where state or federal regulatory authorities monitor and
to some extent control price and quality.8' Allied considerations underlie
the doctrine of "primary jurisdiction." Under this doctrine the antitrust
enforcers may refrain from attacking trade restraints in heavily regulated
industries such as shipping, the airlines, and the railroads, where primary
jurisdiction over the industry is in an effective regulatory body.8"
There are parallels between the state action defense for institutional
providers and the professional exemption defense for medical professionals.
For many years both defenses have appeared to place the industry and
the profession beyond the reach of antitrust enforcement. There were and
are strong public policy reasons for both defenses, however, both seem to
have been weakened by recent Supreme Court action. It seems logical for
institutional health providers to rely on the state action defense because
the health industry is one of the most intensely regulated of all industries.
The current state of that defense will now be examined to ascertain the
extent to which such continued reliance is justified.
The case associated almost interchangeably with the state action de-
fense is Parker v. Brown." The litigation was brought to enjoin enforcement
80 It should be mentioned that a number of state courts have sustained the professional ex-
emption defense under state antitrust laws. One of these cases was Willis v. Santa Ana
Community Hospital Ass'n, 58 Cal. 2d 806, 26 Cal. Rptr. 640 (1962), a treble damage
action by osteopaths against doctors in a hospital under the Cartwright Act (the California
antitrust law) charging a conspiracy to monopolize the practice of medicine. The action
was dismissed, the court holding that the state law did not apply to the professional practice
of medicine. Another state case on this subject is Moles v. White, 336 So. 2d 427 (Fla.
Dist. Ct. App. 1976), cert. dismissed, 345 So. 2d 516 (1978). In this case, the plaintiff doctor
applied for open heart surgery privileges at the defendant hospital. When the application was
denied, he brought an action claiming a conspiracy in violation of the Florida antitrust act,
to deny him those privileges. The court dismissed the action holding that the Florida law did
not apply to the practice of medicine.
8 1 See Blumstein, Calvani, State Action as a Shield and a Sword in a Medical Services Anti-
trust Context: Parker v. Brown in Constitutional Perspective, 1978 DUKE L.J. 389 (1978).
s2 See generally Report of the Attorney General's National Committee to Study the Antitrust
Laws, Ch. VI (1955). Primary jurisdiction questions usually arise when there is a federal
regulatory body in the picture and often the issuei is resolved by a determination that the
regulation does not preclude application of the antitrust laws. See, e.g., United States v. Radio
Corp. of America, 358 U.S. 334 (1959); Silver v. New York Stock Exchange, 373 U.S. 341
(1963).
83317 U.S. 341 (1943).
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by California state officials of a clearly anticompetitive agricultural market-
ing program devised during the Second World War. Plaintiff, a private
producer and packer, argued that the plan was inconsistent with federal law,
in particular the Sherman Act, and hence invalid. Chief Justice Stone's
opinion, holding there was no congressional intent to deprive the states
of their freedom to regulate commerce, had come to be interpreted as in-
sulating from the federal antitrust law all state sanctioned anticompetitive
arrangements.
The many state regulated industries which had, through the years,
taken the Parker v. Brown doctrine for granted were seriously concerned
by the Goldfarb Court's apparent limitation of this defense. In Goldfarb,
the defendant State Bar Association raised the defense on the ground that
it had been designated by the State of Virginia as the administrative agency
to enforce the code of ethics for attorneys in Virginia. In this capacity
the bar had promulgated the challenged minimum fee schedule and de-
clared it unethical for members of the Bar to ignore the schedule.8" In
considering the state action defense the Supreme Court, citing Parker v.
Brown, said: "The threshold inquiry in determining if an anti-competitive
activity is state action of the type the Sherman Act was not meant to pro-
scribe is whether the activity is required by the State acting as sovereign."85
The Court went on to observe that Virginia statutes relevant to the practice
of law were silent on fee schedules and the state had never endorsed the
defendant bar association's ethical opinions.8" Accordingly, there was no
finding of state action regulating attorney fees, and the case was therefore
factually distinguishable from Parker v. Brown. While Parker v. Brown
was cited twice with approval and thus remains a viable precedent, the
Court more precisely defined the requirements for state action by saying that
the "anti-competitive activities must be compelled by direction of the State
acting as a sovereign. 87
The Supreme Court soon had another opportunity to consider Parker
v. Brown and the status of the state action doctrine by way of dictum. In
Virginia State Board of Pharmacy v. Virginia Citizens Consumer Council,
Inc.,8" the Court held that a state statute forbidding the advertising of
prescription drugs was constitutionally invalid as an infringement of the
first amendment's guarantee of freedom of speech. The Court gratuitously
added, however, that: "Virginia is free to require whatever professional
84 421 U.S. 773, 776-77 (1975).
85 Id. at 790.
88 Id. at 790-91.
87 ld. at 791.
88425 U.S. 748 (1976).
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standards it wishes of its pharmacists; it may subsidize them or protect them
from competition in other ways."89 This dictum is consistent with the
recognition in Goldfarb that "States have a compelling interest in the prac-
tice of professions within their boundaries" and that "the State may decide
that forms of competition usual in the business world may be demoralizing
to the ethical standards of a profession." 9
While these pronouncements may be interpreted as approving the police
powers of a state to license and regulate, and thereby create exemptions
from the federal antitrust laws, the Court has recently taken a more re-
strictive view.
In the landmark case Cantor v. Detroit Edison Co., the Supreme Court
took a position limiting the availability of the state action defense.9' In
Cantor, the plaintiff was a retail seller of electric light bulbs. The defendant,
Detroit Edison, had provided "free" light bulbs for many decades to its
customers. The plaintiff alleged that this bulb program was an unlawful
"tie-in" agreement. The defendant claimed the protection of Parker v.
Brown; being closely regulated by the state public utilities commission, it
was required to submit the light bulb program for approval by the com-
mission, had obtained that approval, and now could not discontinue the
program without further approval by the commission." The Supreme Court
denied the defense over a strong dissent, apparently limiting Parker v.
Brown to suits against state officials and designating it thus inapposite to
the case at bar." The Court also stressed that the challenged activity had
originated with the defendant, that the state was neutral, only approving
tariffs submitted to it, and that the state had never made "specific investi-
gation" into it.
94
Justice Stevens, writing for the majority, discussed, without answering,
two significant questions. The first was whether "private conduct required
by state law is exempt from the Sherman Act."9 Goldfarb appeared to have
answered this question in the affirmative."6 Dictum in Cantor supported this
view: "it would be unacceptable ever to impose statutory liability on a party
who had done nothing more than obey a state command."" However, the
89 ld. at 770.
90 421 U.S. at 792.
91428 U.S. 579 (1976).
9
2 Id. at 582-83.
93 Id. at 591-92.
94 Id. at 584-85.
95 Id. at 592.
9See text accompanying notes 84-87 supra. This fact was also noted in Cantor, 428 U.S. at
604 (Burger, C.J., concurring).
07 428 U.S. at 592.
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question remained unanswered in this case because Detroit Edison had
itself initiated the challenged activity rather than acting in response to a
command of the state.9 8
The second question, more relevant to the current activities of the
health industry, was whether the Sherman Act was intended to apply to
a business "pervasively regulated" by the state under standards "funda-
mentally inconsistent" with the Act's purpose of fostering competition.99
Again, the disposition of the action did not necessitate an answer to the
question, since the Court found that there was no specific regulation of
the activity under consideration (the free light bulb program). But the
Court again assumed, in dicta, that a successful defense would have been
presented had the facts shown "pervasive regulation."'"
The Court in Cantor refused to articulate more definite guidelines for
defining the extent of state regulation necessary for a successful defense as
suggested by the dissent. The dissent argued for an antitrust exemption when a
state agency both approved and compelled a private activity."" The majority
rejected this rule, fearing that many state agencies would "grant exemptions
from an important federal law for reasons wholly unrelated either to federal
policy or even to any necessary significant state interest."'' The Supreme
Court thus wishes to reserve discretion to accept the state action defense
on a case-by-case basis without affording the states an opportunity to
carve out areas of exemption by affirmative legislative or agency action.
This approach may be prudent. It is not inconceivable that a state regulated
industry benefitting from a sympathetic political climate and a weak or
even "captive" regulatory body could fashion an anticompetitive regulatory
scheme impermeable to antitrust attack under the standard posed by the
dissent in Cantor.
The Supreme Court recently considered the state action defense in
Bates v. State Bar of Arizona."3 This case challenged the restraints on
advertising imposed by the Supreme Court of Arizona on Arizona lawyers.
In upholding the state action defense the court distinguished Bates from
Goldfarb and Cantor, finding the advertising restraint in this case to be
a clear command of the state acting through its highest court."' However,
the court went on to find the restraint to be repugnant to the first amend-
98 Id. at 593-95.
99 Id. at 595.
10 Id. at 595-97.
10 Id. at 603.
102 Id.
103433 U.S. 350 (1977).
104 Id. at 359,
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ment of the Constitution, which in its guarantee of the freedom of speech
embraces the right to advertise and which overrides all antitrust policies
and exemptions." 5 Consequently, the restraint on advertising imposed by
the Arizona Supreme Court on Arizona lawyers was struck down.
While Bates could be interpreted as restoring some vitality to the
Parker v. Brown defense, it must be remembered that, although the state
action doctrine was sustained, the plaintiff prevailed. It is interesting to
speculate whether the plaintiff's antitrust claim without the first amendment
claim would have sufficed to invalidate the advertising restraint. Changing
the facts of Bates and replacing the advertising restraint with a court pro-
mulgated fee schedule, we have a case much more similar to Goldfarb and
one in which the state action defense might not have fared as well.
Aside from Bates' apparent approval of the state action defense, this
defense has been denied in both Goldfarb and Cantor, as previously noted,
as well as in a host of lower court decisions.' It appears, therefore, that
the state action defense can be relied upon with certainty in only two
circumstances - first, when the defendants are actually state officials, '
and second, when the challenged activity is compelled by state law.'"' But
if the defense is raised under any other circumstances, no matter how
closely regulated the industry or activity challenged, it is likely to be denied." 9
This appraisal of the present utility of the state action defense may
be translated into several practical prognostications for the health field.
Officials of health planning agencies and Professional Service Review Or-
ganizations (PSRO's) should be immune from suit for territorial allocations
and price fixing, respectively." 0 Moreover, entities required to limit pro-
105 Id. at 363-84.
206See, e.g., Kurek v. Pleasure Driveway & Park Dist., 557 F.2d 580 (7th Cir. 1977),
vacated, 435 U.S. 992 (1978) (for reconsideration in light of City of Lafayette v. Louisiana
Power & Light Co., 435 U.S. 389 (1978)); Ballard v. Blue Shield of Southern West Virginia,
Inc., 543 F.2d 1075, 1078-79 (4th Cir. 1976), cert. denied, 430 U.S. 922 (1977) (relying on
Goldfarb and Cantor); Surety Title Ins. Agency, Inc. v. Virginia State Bar, 431 F. Supp. 298
(E.D. Va. 1977), vacated, 571 F.2d 205 (4th Cir. 1978), cert. denied, 98 S. Ct. 2838 (1978);
Feminist Women's Health Center, Inc. v. Mohammad, 415 F. Supp. 1258 (N.D. Fla. 1976)
(relying on Goldfarb).
l0T Cantor v. Detroit Edison, 428 U.S. 579, 591 (1976). See City of Lafayette v. Louisiana
Power & Light Co., 435 U.S. 389 (1978). (State action defense denied when asserted by
city, the Court holding that the defense could be successfully asserted only when the city was
acting pursuant to state direction).
108 Bates v. State Bar of Arizona, 433 U.S. 350, 362 (1977); Cantor v. Detroit Edison, 428
U.S. 579, 592 (1976); Goldfarb v. Virginia State Bar, 421 U.S. 773, 791 (1974).
o10 See 428 U.S. at 595.
1 0 But see Hospital Building Co. v. Trustees of Rex Hospital, 425 U.S. 738 (1976); text
accompanying note 22 supra. The Rex Hospital case was considered by the Supreme Court
only on the interstate commerce defense. It is not known whether the state action defense
was raised at any stage of the proceedings by the planning agency official who was a
defendant.
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duction and refrain from expansion by state planning agencies, for example,
under the National Health Planning and Resources Development Act of
1974,111 should be safe from antitrust attack, as should those health care
providers whose rates are fixed by state agencies, since the regulatory activi-
ties of these agencies are mandated by federal and state statutory enact-
ments. However, there is considerable question whether the state action
defense would apply to voluntary cost containment efforts, including voluntary
peer review, even if the actions are taken to forestall more onerous govern-
ment controls.
3. The Insurance Exemption: The McCarran-Ferguson Act
There have been numerous antitrust cases against the various Blue
Cross and Blue Shield plans and other health insurance companies. In
these cases, the defense of the McCarran Act... is usually raised, often
successfully. This statute states that the business of insurance is exempt
from the antitrust laws to the extent it is regulated by state law. As will
be shown, this defense resembles the state action defense in principle, al-
though it requires quite different conditions to attach.
Prior to the Supreme Court's decision in United States v. South-
Eastern Underwriters Association,"3 the insurance industry was not subject
to federal regulation because it was not considered part of interstate com-
merce."' Consequently, the regulation of the business of insurance was
left entirely to the states. In South-Eastern Underwriters, however, the
Supreme Court changed its position and held that insurance transactions
were subject to federal regulation, including the antitrust laws, under the
power to regulate interstate commerce. 115 In reaction to this decision and
in order to make clear its intent that the business of insurance should re-
main exclusively the province of state regulation, Congress passed the
McCarran Act.
Section 1 of the McCarran Act acknowledges that "the continued
M11 42 U.S.C. § 300K (Supp. 1977). Indeed, Justice Blackmun, in his concurring opinion in
Cantor, noted that the defense should apply to state sanctioned schemes to "improve the per-
formance of the market in fostering efficient resource allocation and low prices." 428 U.S. at
611. In a recent decision, an antitrust action brought under the Sherman and Clayton Acts
against a regional planning agency and a group of hospitals by a plaintiff denied permission
to construct a new hospital, it was held that health planning is exempt under the Parker
v. Brown doctrine. Huron Valley Hospital, Inc. v. City of Pontiac, No. 872-7 (E.D. Mich.
March 2, 1979).
112 15 U.S.C. § 1012(b) (1976). See generally Weller, The McCarran-Ferguson Act's Antitrust
Exemption for Insurance: Language, History and Policy, 1978 DuKE L.J. 587 (1978); Com-
ment, The McCarran-Ferguson Act; A Time for Procompetitive Reform, 29 VAND. L. REv.
1271 (1976).
I'1 322 U.S. 533 (1944).
1' Paul v. Virginia, 75 U.S. (8 Wall) 168 (1869).
125 322 U.S. at 539.
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regulation and taxation by the several States of the business of insurance
is in the public interest."11 The substantive provisions of the Act provide
in pertinent part:
No Act of Congress shall be construed to invalidate, impair, or
supersede any law enacted by any State for the purpose of regulating
the business of insurance . . . unless such Act specifically relates to
the business of insurance: Provided, That . . the Sherman Act, . . .
the Clayton Act, as amended, shall be applicable to the business of
insurance to the extent that such business is not regulated by State
law.11
One exception to the McCarran Act is provided: "Nothing contained
in this chapter shall render the said Sherman Act inapplicable to any agree-
ment to boycott, coerce, or intimidate, or act of boycott, coercion, or
intimidation."l"8
Three conditions determine whether a particular activity is exempt
from the antitrust laws by virtue of the McCarran Act. First, the Act applies
only to the "business of insurance," and it is therefore necessary to determine
whether the challenged activity falls within the scope of that statutory
term. Second, the Act provides that the antitrust laws will apply to the
business of insurance only if that business is not regulated by state law
sufficiently to justify the exemptions. Therefore, even if defendant is found
to be engaged in the insurance business, it is necessary to determine further
whether its activities are regulated by the state. Third, the court must
determine whether the challenged activity constitutes an agreement or act
of boycott, coercion or intimidation which is expressly excepted from the
Act's immunity.
The threshold question for the McCarran defense exemption is whether
the business of insurance is involved. If this is established, together with
state regulation, the defense is effectively asserted, unless the plaintiff can
show a boycott. Thus, most of the cases concentrate on this first element
of the defense.
The inquiry into the meaning of the term "business of insurance" is
usually based on the Supreme Court's definition in SEC v. National Securi-
ties, Inc."9 In that case, the Supreme Court defined "business of insurance"
as follows:
I1 15 U.S.C. § 1011 (1976).
27 Id. at § 1012(b).
118ld. at § 1013(b).
219393 U.S. 453 (1969).
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The relationship between insurer and insured, the type of policy which
could be issued, its reliability, interpretation, and enforcement - these
were the core of the "business of insurance." Undoubtedly, other
activities of insurance companies relate so closely to their status as
reliable insurers that they too must be placed in the same class. But
whatever the exact scope of the statutory term, it is clear where the
focus was - it was on the relationship between the insurance company
and the policy-holder."'
One of the first and leading cases to apply the McCarran Act to the
health insurance field was Travelers Insurance Co. v. Blue Cross of Western
Pennsylvania.'' This was an action under Section 1 of the Sherman Act
claiming that the uniform Blue Cross hospital contract excluded reimburse-
ment for certain costs (hospital construction, uncollectible debts and health
service provided to indigents), thus resulting in lower costs to Blue Cross
and hence to its subscribers. Plaintiff, a competing commercial health in-
surance carrier, claimed that the Blue Cross reimbursement contract con-
stituted an unlawful restraint of trade. The Third Circuit Court of Appeals
found the negotiation of the contract and Blue Cross's relationship with
participating hospitals to be encompassed within the business of insurance.'
The court further found that the state vigorously regulated and in fact
required the reimbursement arrangements under question.'
A subsequent case, Anderson v. Medical Service of the District of
Columbia,2' also asserted this defense with success. Plaintiff, a physician,
challenged the participating provider plan of Blue Shield (Medical Service),
claiming that it was a conspiracy among participating physicians and Medical
Service to force nonparticipating physicians to adhere to medical fees fixed
by Blue Shield. Under the plan, participating physicians were reimbursed
directly by Medical Service for their usual charges, provided that these
charges did not exceed the fees charged for the same service by ninety
percent of the doctors in the community. The participating doctors agreed
to accept the amount received from the insurer as payment in full for serv-
ices rendered and to refrain from charging an excess to the patient. Physi-
cians who did not agree to participate in the plan were not paid directly
by the insurer. Under these circumstances, the insured patient was required
220 Id. at 460.
121 481 F.2d 80 (3rd Cir. 1973), cert. denied, 414 U.S. 1093 (1973).
122 481 F.2d at 82-83.
'
2 2 The Court went on to remark that, even absent the McCarran defense, there was no
Sherman Act violation because the defendant was just trying to "get the best deal possible."
Id. at 84.
124 1976-1 TRADE CASES (CCH) 60,884 (E.D. Va. 1976), afl'd, No. 76-1438 (4th Cir.
March 31, 1977).
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to pay the physician's fee personally and then seek reimbursement from the
insurer. The plaintiff physician claimed that this arrangement constituted
a price fixing agreement.
In holding that the challenged practices involved the "business of in-
surance," immune from attack under the federal antitrust laws, the district
court said:
This Court finds from the record here made that the McCarran-
Ferguson Act exempts it [defendant] from the federal antitrust laws
because its reimbursement methods, as set forth in its subscriber-
participating physician contracts are part of the business of insurance.
The business of insurance refers not only to the relationship between
an insurer such as Medical Service and its policyholders, it refers also
to those other activities which relate so closely thereto that they must
be placed in the same class.12
On similar facts the federal district court for the Northern District
of California reached the same conclusion in Manasen v. California Dental
Services.' Defendant, California Dental Services (CDS), contracted to
reimburse the dental bills of subscribers by making direct payments to
certain "participating" dentists. The contract also included a peer review
system to help determine fees. Under the plan, CDS would compensate
"participating" dentists according to a fixed fee schedule, submitted to and
agreed upon with each dentist in advance, for services to be rendered to
plan members. Any fee schedule submitted by a dentist for approval by
CDS proposing fees above those charged by the dental community was
allegedly rejected by the defendant, unless a committee of peers found the
difference justified. Participating dentists were paid directly by the insurer
and accepted such reimbursement as payment in full.
Plaintiffs alleged that when a subscriber to the plan sought care from
a nonparticipating dentist, the policyholder would receive less than full
125 Id. at f 68,857. The court also said:
Participating physicians are in no way restrained from treating patients who do not sub-
scribe to Medical Service or from selling their services to any other insurance carrier
-they are in no way restrained from charging those entities whatever they wish. Further,
they are in no way restrained from negotiating an agreed fee with those Medical
Service subscribers without paid-in-full coverage or in collecting their fee in full.
Medical Service subscribers are in no way restrained from patronizing a non-participat-
ing physician-the allowance is the same regardless of whether the subscriber goes to the
participating or non-participating physician-the subscribers are so advised.
Non-participating doctors are free to charge their patients, including Medical subscrib-
ers, whatever they deem proper. Id. at 68,857-58.
126 424 F. Supp. 657 (N.D. Cal. 1976). Contra, Royal Drug Co. v. Group Life and Health
Ins. Co., 556 F.2d 1375, 1386 (5th Cir. 1977), aff'd, 47 U.S.L.W. 4203 (1979). This case,
decided after this article was written, narrows the definition of the "business of insurance"
and, consequently, casts doubt on the cases discussed in the text such as Procter and Manasen.
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benefits. They also claimed that the agreements between the insurers and
the participating dentists constituted a conspiracy "to fix the fees charged
by all dentists in the state for dental care, by boycotting dentists who
refuse to restrict their fees in the manner suggested by [the insurer] ... 
The major legal issue in the case was whether defendant's activities,
including its referral of fee schedules to peer review panels and its agree-
ments with participating dentists, were within the "business of insurance"
for the purpose of the McCarran Act exemption. The court, relying in part
on Anderson and Travelers, held that they were, stating:
[A] wide variety of activities which have a substantial effect on rate-
making, including the settlement of claims and the limitations of costs,
are embraced within the definition of "business of insurance."
Plaintiffs here contend that it is an antitrust violation for CDS to
pay service providers prevailing rates for the services rendered to in-
sured patients. It is undisputed that the level of dentists' fees are a
major factor in determining policy premiums. CDS' payment arrange-
ments to service providers are critical elements in CDS' contractual
agreements with its subscribers. These arrangements are intimately
related to the interpretation and implementation of CDS' policies and
to its reliability as an insurer. Accordingly, the Court finds that the
activities challenged in the instant complaint constitute part of the
"business of insurance" within the meaning of the McCarran Act. 2 '
Manasen discussed and relied upon a case in which the McCarran
Act defense was also upheld, Nankin Hospital v. Michigan Hospital Serv-
ice."'29 In Nankin, a small hospital brought suit against Blue Cross under
the Sherman Act when Blue Cross terminated its status as a participating
institution on the basis that it was unnecessary and inefficient. The court
held that contract negotiation with hospitals by the insurer, Blue Cross,
constituted "acts in the conduct" of insurance business, hence within the
scope of the McCarran Act exemption.'
These cases and others have interpreted the McCarran Act to embrace
many aspects of the relationship between carriers and providers of covered
services, including the methods by which health insurance companies bar-
gain with and determine rates of reimbursement for the medical providers
who render services to subscribers and policyholders. This applies whether
the provider is a hospital, as in Nankin and Travelers, or an individual
medical professional, as in Anderson and Manasen.
127 424 F. Supp. at 659-60 (citations omitted).
128 Id. at 666-67 (citations omitted).
129361 F. Supp. 1199 (E.D. Mich. 1973).
1
30 Id. at 1211.
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The second element of the McCarran defense requires a showing that
the activity under attack is regulated by state law. While this is the primary
inquiry when the state action is argued to justify exemption, it is, in com-
parison, the least important element of the McCarran defense. Rarely dis-
cussed at length by the courts, a sufficient degree of state regulation is
usually assumed once it is shown that the defendant is engaged in the business
of insurance. This language from Proctor v. State Farm Mutual Automobile
Insurance Co.' indicates that courts are not inclined to reject the defense
on the basis of an insufficient degree of state regulation.
[In every McCarran Act case which has been reported, the pattern of
state regulation has always been found sufficient to trigger the antitrust
exemption. Such exemption is not affected by whether or not there is
a conflict between the Federal antitrust laws and state regulations,
whether or not the state enforces its regulations or whether such en-
forcement is effective. The mere existence of regulatory statutes capable
of being enforced apparently is all that is required for the McCarran
Act exemption to be applicable." 2
The third requirement of a successful defense based upon the McCarran
Act involves a showing that the defendant's activities did not constitute a
boycott within the meaning of the Act. 13 3 The phrase "boycott, coercion
or intimidation," which appears in the McCarran Act, was taken by Congress
from the Supreme Court opinion in United States v. South-Eastern Under-
writers Association,' which first held that the business of insurance was
"commerce," and thus subject to the federal antitrust laws.' Congress
passed the McCarran Act in reaction to this decision in order to confine
its impact and to assure, among other things, that the federal antitrust laws
would have no application to the insurance industry when regulated by the
states, except when the particularly pernicious practices involved in cases
such as South-Eastern Underwriters occurred.
The wrongful conduct in South-Eastern Underwriters followed the
pattern of "boycotts" traditionally condemned under the antitrust laws. Com-
panies writing fire insurance joined in an association to exclude competing
nonmember insurance companies, their agents and other members of the asso-
ciation who did not adhere to the conspiracy, through coercive devices such
as group refusals to deal with the competing nonmember companies and
their customers.
3 406 F. Supp. 27 (D.D.C. 1975), aff'd, 561 F.2d 262 (D.C. Cir. 1977), pet. for cert. filed,
46 U.S.L.W. 3375 (1977). See also Comment, supra note 112, at 1283-85.
132 406 F. Supp. at 30.
2 15 U.S.C. § 1013(b) (1976).
2s4 322 U.S. 533 (1944).
135 Id. at 539-40.
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As in South-Eastern Underwriters, the hallmark of every boycott con-
demned by the Supreme Court is the use of the coercive force of a collective
refusal to deal. Thus, for example, in Klors v. Broadway-Hale Stores, Inc.,
the Supreme Court defined a boycott as a "concerted refusal by traders to
deal with other traders." '136
Until a recent Supreme Court decision,"S' there was considerable dis-
agreement concerning the proper interpretation of the phrase "boycott,
coercion or intimidation." Many cases adopted a narrow construction of
this exception, confining application of the exception to the boycott of
other insurance companies or insurance agents. 38 The other cases have
employed a broader interpretation of the term, closer to the traditional
antitrust usage: i.e., the statutory language is intended to protect all health
care providers and is not confined to the protection of competing insurance
companies or their agents.'39 The recent Supreme Court case on this point,
St. Paul Fire and Marine Insurance Co. v. Barry, adopted the latter view
and settled the dispute among the circuits.
In Barry, a physician plaintiff alleged that an agreement existed among
medical malpractice insurance carriers to refrain from selling to physicians
dissatisfied with the policies offered by their present insurers. This agree-
ment, the plaintiff alleged, constituted a boycott within the meaning of
the statutory exception, since the agreement amounted to "a concerted
refusal to deal."' °
The trial court, on the defendant's motion, dismissed the action stating:
"the purpose of the boycott, coercion, and intimidation exception was
solely to protect insurance agents or other insurance companies from being
'blacklisted' by powerful combinations of insurance companies, not to affect
the insurer-insured relationship."'' On appeal to the First Circuit, the
decision was reversed, the court of appeals holding that the term "boycott"
136 359 U.S. 207, 212 (1959). To the same effect, see United States v. General Motors Corp.,
384 U.S. 127 (1966); Fashion Originators' Guild v. F.T.C., 312 U.S. 457, 467 (1941).
131 98 S. Ct. 2923 (1978).
138 See Meicler v. Aetna Casualty & Surety Co., 506 F.2d 732 (5th Cir. 1975); Adrissi v.
Equitable Life Assurance Society, 503 F.2d 725 (9th Cir. 1974), cert. denied, 420 U.S. 929
(1975); Pierucci v. Continental Casualty Co., 418 F. Supp. 704 (W.D. Pa. 1976); Mcllhen-
ny v. American Title Ins. Co., 418 F. Supp. 364 (E.D. Pa. 1976); Mathis v. Automobile
Club Inter-Ins. Exchange, 410 F. Supp. 1037 (W.D. Mo. 1976); Mitgang v. Western Title
Ins. Co., 1974-2 TRADE CASES (CCH) 75,322 (N.D. Cal. 1974); Transnational Ins. Co.
v. Rosenlund, 261 F. Supp. 12 (D. Ore. 1966).
13 9 See Proctor v. State Farm Mut. Auto. Ins. Co., 561 F.2d 262 (D.C. Cir. 1977), pet. for
cert. filed, 46 U.S.L.W. 3375 (1977). Ballard v. Blue Shield of Southern W. Va., Inc., 543
F.2d 1075 (4th Cir. 1976), cert. denied, 430 U.S. 922 (1977).
140 98 S. Ct. at 2927.
141 Id.
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should be given its "normal Sherman Act scope.' ' 2 The Supreme Court
agreed, with Justices Stewart and Rehnquist dissenting. Justice Powell, speak-
ing on behalf of the Court, made it clear that the word "boycott" as con-
tained in Section 3(b) of the McCarran Act carries with it the meaning
it had acquired during the years of antitrust litigation:
The language of § 3(b) is broad and unqualified; it covers "any" act
or agreement amounting to a "boycott, coercion, or intimidation." If
Congress had intended to limit its scope to boycotts of competing
insurance companies or agents, and to preclude all Sherman Act
protection for policy-holders, it is not unreasonable to assume that
it would have made this explicit. While the legislative history does
not point unambiguously to the answer, it provides no substantial
support for limiting language that Congress itself chose not to limit.'
B. Antitrust Actions
1. Boycotts
The majority of private antitrust actions in the health field involve
allegations of a boycott. In such suits, the plaintiff claims that a concerted
refusal to deal with him resulted in his exclusion from some area of economic
opportunity. Due to the early success of the defenses discussed above, re-
sulting in dismissal of a case without consideration of the merits, few of
the older cases contain extended discussion of the legality of the economic
activity alleged to be a boycott. Since these procedural and jurisdictional
defenses are not as successful as they were in the past, we can expect more
cases to proceed to consideration of the merits of the alleged antitrust
violations.
This section will first examine boycott cases involving professional
practitioners of the healing arts, usually not medical doctors, who claim
that they were excluded from membership in a state or county medical
242 555 F.2d 3, 8 (1st Cir. 1977).
143 98 S. Ct. at 2934. It should be noted that a danger in asserting the insurance exemption
defense in cases involving non-carrier defendants is that the insurer defendant can be found
to be insulated from attack and thus dismissed out of the action leaving a co-defendant be-
hind. This happened in one of the cases brought by the Ohio State Attorney General. In
that case, Ohio v. Ohio Medical Indemnity, Inc., 1976-2 TRADE CASES (CCH) 61,128 (S.D.
Ohio 1976), the defense was successfully pleaded by the insurance company defendant but
the state medical society remained in the case because it was not found to be involved in
the business of insurance. The state claimed that the medical society controlled the insurer,
Blue Shield, and prevented it from using its bargaining power to reduce physician's fees.
See text accompanying note 203 infra. To the same effect is Pastor v. Hartford Fire Ins. Co.,
1976-1 TRADE CASES (CCH) t 60,783 (C.D. Cal. 1976). There the Los Angeles County
Medical Association remained in the case because it was not found to be in the business
of insurance after the insurance defense was asserted by the insurer. In the Pastor case, a
conspiracy to restrain trade in doctors' malpractice insurance was alleged to exist between
the medical society and the defendant insurance company.
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society or denied the right to admit their patients to a hospital. Membership
in a medical society is often required to obtain malpractice insurance, to
obtain referral of patients from colleagues, and as a necessary prerequisite
to hospital medical staff appointment. Thus, when a podiatrist, osteopath,
or chiropractor is excluded from a medical society or refused admitting
privileges at a hospital, he or she may have a cause of action under the
antitrust laws, especially if the practitioner is being denied the right to
practice as determined by the relevant licensure statute.
In Riggall v. Washington County Medical Society,"' discussed
earlier,' 5 a physician argued that the defendant's refusal to admit him to
membership constituted an illegal boycott. While the court found no effect
on interstate commerce and dismissed the action without consideration of
the merits, it made the following reference to plaintiff's boycott claim:
"Plaintiff has not been prevented from practicing his profession, but in the
final analysis his complaint is that he could practice it more profitably but
for the acts of the defendants. The Sherman Anti-Trust Act was not pri-
marily to protect the individual but to protect the general public eco-
nomically . *..."1' This statement illustrates an antitrust principle which
must form a part of any successful action based upon boycott. The alleged
antitrust offense must be shown to have injured some segment of the public
and also to have injured the plaintiff, as part of that public. Unless plain-
tiff has sustained injury as a result of defendant's antitrust violation, he
has no standing to sue."'
In Wolf v. Jane Phillips Episcopal-Memorial Hospital Center,"' an
osteopath claimed a boycott by two hospitals. The interstate commerce
defense was successfully interposed. This same defense was also sustained
in another boycott case, Spears Free Clinic and Hospital for Poor Children
144 249 F.2d 266 (8th Cir. 1957), cert. denied, 355 U.S. 954 (1958).
145 See text accompanying notes 39 and 41 supra.
146 249 F.2d at 268.
147 There are other antitrust cases in the health field illustrating a plaintiff's lack of standing. In
Council for the Advancement of the Psychological Professions and Sciences, Inc. v. Blue Cross
Ass'n, No. 623-73 (D.D.C. Nov. 5, 1974), the plaintiffs sued claiming that a provision of
the Blue Cross contract covering their patients required prior referral by a medical doctor.
While the case was dismissed as moot, the provision having been altered, the court said that
the plaintiffs lacked standing for failure to show sufficient nexus between the alleged violation
and plaintiffs practice. In Meyer v. Massachusetts Eye & Ear Infirmary, 330 F. Supp.
1328 (D.C. Mass. 1971), the plaintiff was a doctor who claimed that a condition requiring
that he give free time to treat clinic patients was an antitrust restraint on his practice. He
also raised a number of claims concerning the inadequacy of care rendered to patients he
was required to treat arising from the free care requirements. The court dismissed the
action, ruling that the plaintiff doctor lacked standing to raise the patient's rights. See also
Stern v. Lucy Webb Hayes Nat'l Training School for Deaconesses and Missionaries, 367
F. Supp. 536 (D.D.C. 1973), supplemented, 381 F. Supp. 1003 (1974).
148 513 F.2d 684 (10th Cir. 1975); see text accompanying note 45 supra.
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v. Cleere." ' The boycott in Spears was by city, county and state medical
societies against a chiropractic hospital.
Only two boycott cases have been reported in which the court has
actually addressed the merits. The first of these is the well-publicized 1943
case, American Medical Association v. United States in which the Supreme
Court held that the AMA had violated the Sherman Act in its efforts to
oppose a prepaid medical plan.1"' It is important to note that no showing
of effect on interstate commerce was necessary in this case because the
suit was brought under Section 3 of the Sherman Act, which extends the
law to the District of Columbia. The defendant medical association had
organized a boycott to prevent doctors associated with the newly formed
Group Health Association of Washington, D.C., from securing hospital
admitting privileges.
The second case in which the court considered the merits of a boycott
claim also originated in the District of Columbia. In Levin v. Doctors' Hospi-
tal,' a podiatrist, excluded from medical staff appointment at a hospital,
claimed to be the victim of a boycott. The court, however, found that the
alleged boycott was only an ancillary result of a hospital rule enacted for the
internal regulation of the hospital. The rule was intended to raise ethical
standards and enhance the quality of services rendered in the hospital.'
149 197 F.2d 125 (10th Cir. 1952); see text accompanying note 41 supra.
150317 U.S. 519 (1943).
151233 F. Supp. 953 (D.D.C. 1964), rev'd on other grounds, 354 F.2d 515 (D.C. Cir. 1965).
In a more recent case plaintiff claimed violation of sections 1 and 2 of the Sherman Act
when his application for medical staff privileges was denied. The court refused to dismiss
the action on a motion for summary judgment, Robinson v. Magovern, 456 F. Supp. 1000
(W.D. Pa. 1978).
152 This is the "quality defense" and is perhaps the most promising of all defenses for
health industry defendants. Its application is also illustrated in Nankin Hospital v. Michigan
Hospital Services, 361 F. Supp. 1199 (E.D. Mich. 1973), a case in which a McCarran
defense was sustained. See text accompanying note 129 supra. The court there made a finding
that the challenged standards were not adopted for anticompetitive reasons and said:
When a non-profit corporation promulgates standards designed primarily to promote the
public welfare and not to lessen competition, the resulting restraint, if any, is reasonable
and therefore not. violative of the Sherman Act. Board of Trade of the City of Chicago
v. United States, 246 U.S. 231 (1918); Roofire Alarm Co. v. Royal Indemnity Co.,
313 F.2d 635 (6th Cir. 1963), cert. denied, 373 U.S. 949 ....
id. at 1207.
In an accompanying footnote the court stated: "The District Court in Roofire Alarm
Co. v. Royal Indemnity, supra, held that the Sherman Act is not intended to reach normal
and usual contracts or combinations which are incidental to lawful purposes and are in-
tended to further legitimate trade." id. at 1207 n.26. As indicated in Nankin, the defense
has its roots in the "rule of reason" set out in Chicago Board of Trade, 246 U.S. 231 (1918).
In Chicago Board of Trade, the Court analyzed the price fixing effect of a Board rule specify-
ing prices to be charged after the close of trading hours on the exchange according to the
rule of reason. See also United States v. Columbia Pictures, 189 F. Supp. 153, 178 (S.D.N.Y.
1960). Like Chicago Board of Trade and Columbia Pictures, the effect of the restraint of
trade in Levin and Nankin was found to be ancilliary to the primary and valid purpose of
providing quality medical care. It would seem that, in the absence of anticompetitive intent
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There are numerous "medical staff privileges" cases with similar facts
which have not alleged a violation of antitrust legislation. Some of these
cases are brought on constitutional grounds alleging a denial of due process
153
and some are brought under civil rights statutes."' It seems likely that there
will be more medical staff privilege cases claiming under the federal or
state antitrust laws'55 as attorneys become more aware of possible appli-
cability of the statutes to health care providers.
One notable boycott case which had all the earmarks of the classic
restraint of trade was settled and therefore not reported. Dr. Edward B.
Dietrich, an Arizona heart surgeon of international reputation, brought
suit with the Arizona Heart Institute against local physicians, the AMA,
and the county medical society. Dietrich and the Institute, which he had
founded, charged defendants with engaging in a boycott, defamation, in-
vasion of privacy, and violation of Dietrich's civil rights in their effort to
ruin him professionally and financially. Dietrich claimed that defendants
had acted against him because the increasing volume of open heart surgery
being performed at the Institute was reducing the practice of certain de-
fendants. Dietrich showed that charges of incompetence and unethical con-
duct which defendants had brought against him had been dismissed by the
state board of medical examiners. He also showed that the local planning
authority, dominated by defendants' supporters, had denied him the right
to set up a free-standing heart institute. These and other proofs apparently
impressed the defendants and persuaded them to settle the case for an
amount reported to be in excess of a half million dollars.
(see text accompanying note 79 supra), proof that the primary purpose of an activity chal-
lenged under the antitrust laws is the establishment of high quality patient care standards,
would be persuasive evidence of "good faith" as defined by the Feminist case. See text ac-
companying note 75 supra. This is a defense that is seen more frequently in cases now being
litigated involving health professionals. See, e.g., In re American Medical Ass'n, F.T.C.
Docket No. 9064 (Filed Dec. 19, 1975) (the attack by the FTC on AMA advertising
restraints); cases discussed in the text accompanying notes 159-162 infra.
153 See, e.g., Kentucky Ass'n of Chiropractors, Inc. v. Jefferson County Medical Soc'y, 549
S.W.2d 817 (Ky. 1977).
154 See, e.g., Aassum v. Good Samaritan Hospital, 542 F.2d 792 (9th Cir. 1976).
155 Mention should be made of two boycott cases brought under state antitrust laws,
although both were dismissed on the grounds of the professional exemption before the merits
were reached. The first case is Willis v. Santa Ana Community Hospital Ass'n, 58 Cal. 2d
806, 376 P.2d 568, 26 Cal. Rptr. 640 (1962). Willis was a treble damage action by osteo-
paths against hospital doctors under the Cartwright Act (the California Antitrust Law)
charging a boycott and a conspiracy to monopolize the practice of medicine. The action
was dismissed, the court holding that the state law did not apply to the professional
practice of medicine. The second case is Moles v. White, 336 So. 2d 427 (Fla. Dist. Ct.
App. 1976), cert. dismissed, 355 So. 2d 516 (Fla. Sup. Ct. 1978). In Moles, the plaintiff
medical doctor applied for open heart surgery privileges at the defendant hospital. When
the application was denied, he brought an action claiming a boycott and a conspiracy to
deny him those privileges in violation of the Florida Antitrust Act. The court dismissed the
action holding that the Florida law did not apply to the practice of medicine.
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Currently, considerable enforcement activity by state and federal
agencies involves alleged boycotts of health maintenance organizations
(HMO)."' In Ohio ex rel. Brown v. Mahoning County Medical Society,'57
for example, the Ohio Attorney General has brought an action against two
medical organizations and several individual doctors charging that they have
engaged in a boycott to prevent doctors from working for a new, union-
sponsored HMO. The action is pending.
Further, the Federal Trade Commission has been vigorously in-
vestigating possible boycotts of HMO's. In pursuit of data, the Commission
is surveying approximately two hundred HMO's to determine whether they
encountered anticompetitive restraints during their period of development.
The investigation, which began in April 1977, was prompted by a consent
order entered into with the Spokane Blue Shield Plan in September 1976.
The FTC had charged the Plan with refusing to deal with a small HMO in
Deer Park and the doctors who worked for it. The similarity to the 1943
American Medical Association v. United States case discussed earlier is
striking. When prepaid group practices such as Kaiser, Group Health As-
sociation of America in Washington, D.C., and Health Insurance Plan in
New York were first developed in the 1930s and 1940s, organized medicine
as represented by the AMA felt the threat of group practice. The suit brought
by the Ohio Attorney General against a county medical society for boycotting
an HMO shows that private practitioners of medicine are still fearful of
prepaid medical care organizations. The recent growth of HMO's, however,
is likely to proceed at the expense of the existing indemnity insurers like
the Blue Shield Plans. Hence, history is repeating itself, with health in-
surers along with organized medicine as defendants.
The FTC has also been investigating the AMA for allegedly attempting
to eliminate the chiropractic profession by boycott and for other actions
violative of the antitrust laws. This inquiry began in late 1975 as a result
of the disclosure of certain internal AMA documents to the House Over-
sight and Investigations Subcommittee by an anonymous informant within
the AMA. In February 1976, the FTC also announced that it was in-
vestigating the nation's seventy-one Blue Shield Plans to determine if they
were dominated and controlled by local medical societies. Another FTC
investigation seeks to determine if there is any evidence that the AMA or
any affiliates have restrained the supply of physicians or health services.
In that investigation, the FTC is examining the AMA's role in the accredita-
15 See generally Kissam, Health Maintenance Organizations and the Role of Antitrust Law,
1978 DUKE L.J. 487 (1978).
257 No. C 76-168Y (N.D. Ohio Aug. 24, 1976). See also Group Health Cooperative of Puget
Sound v. King County Medical Soc'y, 39 Wash. 2d 586, 237 P.2d 737 (1951).
Winter, 1979]
35
Borsody: Antitrust and the Health Industry
Published by IdeaExchange@UAkron, 1979
AKRON LAW REVIEW
tion of medical schools, recognition of medical specialties, licensure of
allied health professions, and restriction of development of alternative
modes of health care delivery. As part of this investigation, the FTC sent
out subpoenas on December 27, 1976, to specialty boards for allergy and
immunology, anesthesiology, family practice, internal medicine, nuclear
medicine, otolaryngology, pathology, pediatrics, radiology, surgery and
urology.
Exclusive contracts for the rendition of hospital-based specialty services
have also raised the legal issue of boycott. In such arrangements a hospital
or other health institution agrees to deal only with a designated physician or
group of physicians in a designated specialty, thus closing the department
to other qualified persons. The hospital usually justifies this as a way of
ensuring quality, an argument strengthened by numerous cases which have
imposed increasing responsibility on the corporate hospital for malpractice
of the hospital's attending physicians.
Charges of boycott arising from such exclusive contracts fall into two
categories. In the first, a hospital has an exclusive contract with A, and B
sues, claiming an exclusion. In the second, the hospital terminates its con-
tract with A, who sues, claiming an exclusion.158 Two examples of the first
variety follow.
In Powsner v. St. Joseph's Mercy Hospital,'59 the defendant hospital had
contracted with a group of cardiologists to provide diagnostic and therapeutic
cardiological services to the hospital, including cardiac catheterizations. No
other physicians could use the hospital equipment to perform the catheter-
izations. Plaintiff, a cardiologist, brought an action under the antitrust laws
of Michigan claiming, among other allegations, that her exclusion was a
restraint of trade and a boycott. The court noted that, under state restraint
of trade laws, only unreasonable restraints were forbidden; hence, the "rule
of reason" must be applied to the facts. Thus, the intent of the defendants
was of significance and exclusion of plaintiff was not a violation per se.
This action was dismissed by the court, which said:
With respect to plaintiff's allegations of the statutory violation, the
Court finds that the parties defendant herein neither singly nor in con-
cert had any intent or purpose at any time to create, affect or maintain
a monopoly or restraint of trade. The Court finds that at all relevant times
the defendants' herein sole purpose and intent was to provide the high-
est quality of patient care available.
1V Cases challenging exclusive contracts have also been brought on grounds other than
restraint of trade but without success. See, e.g., Bank v. Palo-Stanford Hospital, 234 Cal.
App. 2d 377, 44 Cal. Rptr. 572 (1965).
'59 No. 5279 (Mich, Cir. Ct,, Washtenaw Co., Dec. 1, 1977).
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The medical education system is the epitome itself of a selective process.
Special and subspecialization is a further selective process. The
provision of such services often dictates a high degree of selectivity
in order to assure only those most qualified provide the services and
direction and control. The process of specialization in all areas has
increased as scientific and technological advances have been made.
The Court finds that whatever restraint may be incidentally occasioned
by the subject contract, in the sense that all contracts affect trade, when
weighted against the public benefits as outlined, it is reasonable.'
Earlier litigation in Arizona on similar facts had reached the same re-
sult in Datillo v. Tucson General Hospital.' The hospital had an exclusive
contract for nuclear medical services. The action was brought by an ex-
cluded specialist under the Arizona State antitrust laws. The plaintiff was
awarded a $40,000 judgment in the trial court, but this was reversed on
appeal.
The court of appeals of Arizona also applied the "rule of reason," ap-
proving the exclusive contract arrangement on the following grounds:
such contracts were needed for control and standardization of procedure
and effective, efficient operation of the department; that they give the
Board of Trustees great ability to monitor the departments to ensure
that the standard is being maintained because of the more limited num-
ber of people actually participating; better patient care is achieved
because of better scheduling and higher quality of results; they operate
more economically; they provide consistency of training of technicians;
allow doctors to keep up with current cases in the field; and create a
pool of medical knowledge available to all members of the staff to
utilize. 6 '
This kind of argument, which uses considerations of the quality of care to
justify what in another setting would be a clear restraint of trade, was
discussed in Feminist Women's Health Center, Inc. v. Mohammad,'" noted
earlier,' and will be considered by the courts more frequently as they reach
the merits of antitrust allegations involving health care providers."
The second type of boycott case involving the termination of exclusive
contracts is illustrated by Harron v. United Hospital Center, Inc.66 In this
160 Id. slip op. at 55.
16123 Ariz. App. 392, 533 P.2d 700 (1975).
262 Id. at 704-05.
"ea 415 F. Supp. 1258 (N.D. Fla. 1976).
I" See text accompanying note 75 supra.
2e5The quality of care defense is discussed further in text accompanying note 153 supra.
266 522 F.2d 1133 (5th Cir. 1975), cert. denied, 424 U.S. 916 (1976).
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case plaintiff, a physician, claimed that termination of his exclusive con-
tract to operate the radiology department of a hospital violated both his
federal civil rights and the federal antitrust statutes. The district court granted
the physician a preliminary injunction. When the defendant appealed this
ruling, the Fourth Circuit dismissed the action, stating:
Whatever may be the law of contracts, it is frivolous to urge that the
employment of a single doctor to operate the radiology department of
a hospital invokes the Sherman Act and the civil rights statutes pleaded.
On remand, the district court will be instructed to dismiss the complaint
for want of a substantial federal question and a consequent lack of
jurisdiction."'
Although the Harron case does not discuss the point, a distinction must
be made between a unilateral refusal to deal and an agreement or concerted
refusal to deal. The former is permitted under antitrust law and is illustrated
by Harron. The latter is condemned by the antitrust laws as a boycott and is
illustrated by the cases alleging that health care providers have agreed among
themselves to withhold services from patients entitled to a particular source
of reimbursement or those alleging refusal of third party reimbursement
sources to deal with a particular class of providers.
An example of a provider boycott case is Ohio ex rel. Brown v. Alliance
Dental Services,'68 brought in Ohio against dentists who refused to treat Medi-
caid patients until the fees were raised. While these cases have been threat-
ened widely for years by local government officials, few have been brought,
perhaps because the situations that provoke the threats are so quick to arise-
and collapse. An investigation is currently underway by the New York
Attorney General under the state antitrust laws of a possible boycott by
doctors in New York City and Long Island of patients whose fees are paid
by workmen's compensation and the no-fault laws.'
An example of the other side of the coin, a boycott of providers by an
insurance company, is the case of Ballard v. Blue Shield of West Virginia,
167 Id. at 1134. A similar case brought under state due process laws for termination of an ex-
clusive cardiac consultation contract was dismissed on quality of care grounds. Adler
v. Montefiore Hospital Ass'n of Western Pa., 453 Pa. 60, 311 A.2d 634 (1973), cert. denied,
414 U.S. 1131 (1974).
168 1976-1 TRADE CASES (CCH) 60,955 (Ohio C.P. 1976). See generally Weller, Medicaid
Boycotts and other Maladies from Medical Monopolists, 11 CLEARINGHOUSE REV. 99 (1977).
See also DeGregorio v. Segal, 443 F. Supp. 1257 (E.D. Pa. 1978) (Action by Medicaid re-
cipients against nursing homes alleging a boycott; motion for dismissal on standing grounds
denied). Contra Ajello v. Moffie (Conn. Sup. Ct., Hartford Co. Jan. 3, 1977).
189 Motions to quash subpoenas issued by the Attorney General were recently denied, the
court finding that: "although medicine is a profession, the United States Supreme Court
held that, individual physicians who engage in or foster a medical boycott, are subject to
[the antitrust laws]." In re Hirshorn, 402 N.Y.S,2d 520 (1978).
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Inc.'" mentioned above in the discussion of the professional exemption.
In this case chiropractors successfully claimed a boycott by health insurers
who refused to provide coverage for chiropractors." '
2. Price Fixing
Price fixing is the classic restraint of trade. The Department of Justice
has recently brought actions claiming that the use of relative value scales pro-
mulgated by various professional societies constitutes price fixing. These
cases, United States v. American Society of Anethesiologists," s and United
States v. Illinois Podiatry Society,"" are part of antitrust enforcement activity
aimed at prohibiting the use of relative value scales. Such scales set forth a list
of comparative values for designated surgical and medical procedures. The
comparative values can be easily converted into monetary fees by the
application of a dollar conversion factor. The similarity to the minimum
fee schedule litigated in Goldfarb is apparent. The FTC has signed consent
orders prohibiting further use of relative value scales with the American
Academy of Orthopaedic Surgeons on May 28, 1976,1'" with the American
College of Obstetricians and Gynecologists on June 17, 1976,7"e and with
the American College of Radiology on September 13, 1976.17" Consent
orders have also been entered with several state and local medical societies.
Since most medical professional organizations have stopped using relative
value scales, this type of enforcement activity should become less widespread.
Relative value scales or any type of "fee schedule" promulgated by
the profession itself must be sharply distinguished from rate regulation by
governmental authorities. When government regulates rates directly, the
doctrine of Parker v. Brown, discussed earlier provides an exemption from
170 543 F.2d 1075 (4th Cir. 1976), cert. denied, 430 U.S. 922 (1977).
1 Text accompanying note 63 supra.
172 In addition, chiropractors have brought antitrust actions against the AMA and other
medical associations on the grounds that acceptance and enforcement of the AMA Code
of Ethics which proscribes voluntary association between medical doctors and chiropractors
constitute a "restraint of trade." New Jersey Chiropractic Soc'y v. Radiological Soc'y of
N.J., 156 N.J. Super. 365, 383 A.2d 1182 (1978) (Summary judgment motion by defendants
raising the usual jurisdictional defenses denied); Slavek v. AMA, No. 77-1726 (E.D. Pa.
1977).
A recent boycott case dismissed on McCarran grounds is St. Bernards Gen. Hospital, Inc.
v. Hospital Serv. Ass'n of New Orleans, Inc., 1978-1 TRADE CASES (CCH) V 61,868 (E.D.
La., Oct. 17, 1978), where providers alleged that Blue Cross refused to deal with them. A
prior dismissal of this same case on interstate commerce grounds was reversed by the
Fifth Circuit. See note 38 and accompanying text supra.
171 No. 75 Civ. 4640 (S.D.N.Y. Sept. 22, 1975).
174 Consent decree entered, 1977-2 TRADE CASES (CCH) 61,767 (December 6, 1977).
175 In re The American Academy of Orthopaedic Surgeons, 88 F.T.C. 968 (1976).
176 In re The American College of Obstetricians and Gynecologists, 88 F.T.C. 955 (1976).
177 In re The American College of Radiology, 89 F.T.C. 144 (1977).
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allegations of antitrust violation."' The State of Wisconsin, exhibiting a
degree of caution, recently requested review by the Department of Justice
of a proposed program to set prospective hospital rates. The program,
established under 1975 legislation, authorized Wisconsin's Department of
Health and Social Services to contract with the Wisconsin Blue Cross and
the Wisconsin Hospital Association to jointly review proposals by individual
hospitals for rate increases. Included in the program was a provision for
appeals and for the development of standards for determining the reasonable-
ness of rates. The Department of Justice approved the program.'"
The ethical prohibitions on advertising by members of the medical
profession is currently being challenged by both private parties and gov-
ernmental agencies. 8 ' The FTC has filed a complaint against the American
Dental Association for its stricture against advertising,'' and has challenged
this basic premise of professionalism by attacking the AMA code of ethics
in the case of In re American Medical Association, filed December 19,
1975.182 The FTC argues that the prohibition of advertising is a violation of
Section 5 of the FTC Act, since the absence of advertising allegedly results
in price fixing and in the allocation of customers. Prices become fixed
because physicians have no incentive to compete on that basis to attract
patients, and customer allocation results from patients' lack of information
upon which to base their choice of physicians. Moreover, the medical pro-
fession's traditional prohibition on solicitation of patients exacerbates the
situation produced by the ban on advertising.
Health Systems Agency v. Virginia State Board of Medicine,8 ' a private
action, raised these same issues. The case arose from an attempt to compile
a listing of doctors and their fees for an area covered by the plaintiff Health
Systems Agency. The 1977 Supreme Court decision in Bates v. State Bar
of Arizona,' holding that certain ethical restrictions on advertising by at-
torneys were unconstitutional, can be expected to have at least as much
178 See text accompanying note 111 supra.
179 Business Review Letter dated July 5, 1977. The Department has a business review pro-
cedure under which proposed actions can be submitted for review. 28 C.F.R. § 50.6 (1978).
The Department's procedure when "approving" a proposed action, such as the one described
in the text, is to state that it has "no present intention to institute enforcement proceedings"
against the proposed action.
'
80 See Canby, Gellhorn, Physician Advertising: The First Amendment and The Sherman Act,
1978 DuKE L.J. 543 (1978).
is, 3 TRADE REG. REP. (CCH) 1 21,255, F.T.C. Docket No. 9093 (Jan. 4, 1977).
182 F.T.C. Docket No. 9064 (Filed Dec. 19, 1975). A number of other professional prac-
tices and AMA rules are called into question in this procedure. They include prohibitions on
patient solicitation, "corporate practice" of medicine, and partnerships between physicians
and non-physicians.
183 424 F. Supp. 267.
184433 U.S. 350 (1977).
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effect on the medical profession as did Goldfarb. There now seems little legal
basis for an ethical prohibition on the advertising of medical fees for first
and follow-up visits, representative procedures, and of other basic facts about
the practice of an individual or an institution.
A possible new area of litigation activity could develop challenging
peer review, alleging that review of fees is tantamount to price fixing. A peer
review committee reviews fees submitted to it to determine whether they
are "usual, reasonable, and customary." In peer review, health insurance
carriers submit their fees for review by a committee of "peers" - i.e.,
health care providers. With the increasing emphasis on peer review,
whether voluntary or imposed by legislation like the Professional Services
Review Organization legislation18 and Titles Eighteen"8 6 and Nineteen 8
utilization review for Medicare and Medicaid reimbursement, the providers
subjected to the review process may counterattack with antitrust allegations.
To date the only such cases have involved voluntary peer review, probably
because a defense based on Parker v. Brown would very likely be valid and
effective for peer review required by the legislature. 8 '
Several cases have been filed in which chiropractors have attacked the
voluntary peer review of fees and quality of care conducted by a state or
national society, usually joining insurance companies as defendants. 9 The
chiropractors claim in these cases that the peer review process fixes prices
by putting an upper limit on fees. Two of the cases are Pireno v. New York
State Chiropractors Association' and Bartholomew v. Virginia Chiropractors
Association. 9' In Bartholomew a motion to dismiss on the usual jurisdictional
basis was denied and the case was set down for trial,' while in Pireno the
action was dismissed on McCarran grounds, the court finding the peer te-
18542 U.S.C. § 1320c (1976).
186 Id. at § 1395X(k).
'
87 Id. at § 1396 a(19), (26).
lag See text accompanying note 111 supra. The PSRO legislation has been upheld as constitu-
tional. Association of American Physicians and Surgeons v. Weinberger, 359 F. Supp. 125
(N.D. IIl. 1975).
189The Antitrust Division issued a Business Review Letter, dated March 2, 1977, with re-
spect to the voluntary peer review program of a national chiropractic organization. The letter
noted that the purpose of the peer review committee "is to act as mediators in disputes be-
tween third party reimbursement organizations and chiropractic care organizations by
attempting to settle disputes over the amount of particular fees charged by providers" and
that the "Committees act in a purely advisory capacity." While stating no intent to challenge
the procedure, the letter added that the Antitrust Division "could change its decision" if
future evidence disclosed "an intent to control or upwardly influence" fees charged.
190 76 Civ. 4309 (S.D.N.Y. Sept. 28, 1976).
'9' 77-0062(R) (W.D. Va. April 7, 1977).
1
9 2 1d.
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view process encompassed within the "business of insurance.""19 In another
case, Ettenson v. Dutchess Co. Medical Society,"' a physician sought to
enjoin the activities of a medical society's peer review committee as it applied
to him. He claimed that the proper forum for reviewing the fee in question
was arbitration under the state's no-fault law because the fee was for treat-
ment of injuries sustained in an automobile accident. He also argued that
the Committee's actions defamed him and violated the Sherman Antitrust
Act. The doctor's suit was dismissed on the grounds of failure to exhaust ad-
ministrative remedies. The court did not treat the merits of the antitrust
argument in its opinion, merely observing that "no suggestion was made
as to any specific monetary amount or any reference made to any fixed
schedule" by the peer review committee. Should the Bartholomew case be
decided the same way, on the merits, it is unlikely that there will be more of
this type of action. However, should the federal courts take a different view
and find that peer review indeed has the effect of fixing prices, the filing
of this type of suit will be encouraged. One of the current doctrines of the
nation's public health policy is that peer review can help contain the rapidly
rising costs of health care. Peer review, therefore, has been widely en-
couraged. However, health providers who engage in this process could
find themselves caught between the prohibitions of antitrust policy and those
of public health policy if the plaintiffs prevail in any of the cases noted
earlier. "
3. Mergers, Tie-ins and Other Cases
The antitrust laws prohibit the elimination of competition by merger
of competing entities." This tactic has not found much use in the health
industry. The fragmentation of the industry, its multiplicity of providers, hos-
pitals, and individual practitioners, would probably minimize the intended
anticompetitive impact of any such merger. A few recent cases, however,
have suggested that despite this fragmented nature, health industry mergers
do have antitrust implications.
193 76 Civ. 4309 (S.D.N.Y. Mar. 15, 1979) appeal docketed, No. 79-7307 (2d Cir. Apr. 15,
1979). This decision was made after the Supreme Court's construction of this aspect of Mc-
Carran in Royal Drug Co. v. Group Life, 47 U.S.L.W. 4203 (1979). See note 126 supra.
194 N.Y.L.J June 29, 1977, p.17, co.4 (Sup. Ct. Dutchess Co.).
195 See text accompanying note 192 supra. A final price fixing case should be mentioned. In
Webster County Memorial Hospital, Inc. v. United Mine Workers of America Welfare and
Retirement Fund of 1950, 536 F.2d 419 (D.C. Cir. 1976), the plaintiff hospital charged the
defendant with price fixing under § 1 of the Sherman Act because the Fund had repeatedly
refused, over a period of time, to pay the entire amount of price increases asked by plain-
tiff for services to the Fund's insureds. The court dismissed the action finding "no allegation
of monopoly" and "nothing unreasonable in the actions of the Fund." Id. at 420.
126See note 16 and accompanying text supra. Mergers may also be attacked under the Sher-
man Act. See, e.g., United States v. Columbia Steel Co., 334 U.S. 495 (1948).
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The leading case to date is City of Fairfax v. Fairfax Hospital Associ-
tion, 1 7 brought under Sections 1 and 2 of the Sherman Act, instead of Sec-
tion 7 of the Clayton Act. The suit was filed by a group of doctors and
a municipality that opposed the transfer of a proprietary hospital to a pub-
licly operated hospital authority. They claimed that the merger into the
authority would decrease competition and increase prices, thus adversely
affecting future patients as well as causing a loss of property taxes to the
city. The lower court dismissed the action on the basis that there was no
substantial effect on interstate commerce and further because the doctrine
of state action exempted the activity from antitrust attack. The lower court
further found that the plaintiffs lacked standing to complain of the alleged
injuries, which were found to be speculative and conjectural. The decision
was rendered three weeks before the Supreme Court released its opinion in
Hospital Building Co. v. Trustees of Rex Hospital."8 Accordingly, Fairfax
was reversed on appeal"' on the authority of Rex Hospital. On writ of
certiorari to the Supreme Court, the Fourth Circuit's judgment was vacated
for reconsideration in light of City of Lafayette v. Louisiana Power & Light
CO. 200
Another merger case, while merely an adjunct to a corporate conflict
between an acquiring and a "target" corporation, resulted in the first judicial
assessment of relevant market considerations in the health industry. The
case, American Medicorp v. Hummana, Inc.,"°1 warrants careful analysis.
Defendant made a tender offer to the shareholders of plaintiff. Plaintiff's
management, hostile to the proposed acquisition, filed the antitrust action
as a defensive measure, claiming that the merger would lessen competition.
Both parties were in the same business, namely, the ownership or manage-
ment of hospitals. The court denied a motion for a preliminary injunction
by plaintiff. Plaintiff had argued that the merged entity would control 29.5%
of all proprietary hospital short-term acute care beds in the country. The
court found, however, that the new entity would only control 1.7% of
all short-term acute care beds in community hospitals. The court reasoned
that, in an industry characterized by large numbers of competitors, this
197 1976-2 TRADE CASES (CCH) t 60,999 (E.D. Va. May 3, 1976).
198 425 U.S. 738 (1976). See text accompanying note 31 supra.
199 562 F.2d 280 (4th Cir. 1977). There is also a discussion of the state action defense in
the Fourth Circuit opinion which, over two lengthy dissents on this issue, limits the defense
to actions compelled by state agencies, as distinct from local government agencies.
200435 U.S. 992 (1978).
201 445 F. Supp. 589 (E.D. Pa. 1977). A court, in considering the legality of a merger, must
first determine the area of effective competition of the relevant market within which the
merging entities operate, then the share of this market held by each entity and the resultant
combined entity. It is this latter share that must be considered to determine if competition will
be adversely affected by the merger.
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percentage did not constitute a threat to competition. The court held that
the disposition of this merger case did not require any distinction between
the beds of a proprietary hospital and those of a voluntary, nonprofit hos-
pital. In addition, the court noted that the local health systems agencies,
established under the National Health Planning and Resources Development
Act,2"' regulated all construction of beds. After the denial of the preliminary
motion, the defendant acquired a controlling interest in the plaintiff cor-
poration.
In one of the cases initiated by the Ohio Attorney General as part
of his program to enforce antitrust legislation in the health field, Ohio v.
Ohio Medical Indemnity, Inc., 02 a potentially far-reaching argument was
made that the Ohio State Medical Association was in violation of Section
Seven of the Clayton Act as well as Sections 1 and 2 of the Sherman
Act by virtue of its control over the state Blue Shield Plan. The State of
Ohio charged the Blue Shield Plan (the largest single payor of doctor bills
in the state) with failure to effectively use its bargaining power to reduce
the costs of physicians' services since the Board of Blue Shield was domi-
nated by members of the Medical Association."0 4 The Blue Shield Plan
successfully asserted the McCarran Act defense by claiming that it was
engaged in the business of insurance. It was dismissed as a defendant. The
Medical Association remained as the defendant in the action. On March
22, 1979, the lawsuit was settled, the Ohio State Medical Association re-
linquishing control of the Blue Shield Plan."0 5 The FTC announced in
February 1976 that it was investigating the other seventy Blue Shield Plans
in the country to determine whether similar relationships existed with the
same anticompetitive effects as those alleged in the Ohio Medical Indemnity
case.
A tie-in agreement has been defined as: "an agreement by a party to
sell one product, but only on the condition that the buyer also purchases a
different (or tied) product." '  While tie-ins have been involved in some
of the cases discussed above, as yet no case in the health industry has raised
the issue squarely. In Boddicker v. Arizona State Dental Association,"0 7 a
202 42 U.S.C. § 300K (Supp. 1977).
203 1976-2 TRADE CASES (CCH) 61,128 (S.D. Ohio 1976). See note 143 supra.
204 Id.
205 Plain Dealer, Mar. 23, 1979, at 1, col. 2. The Ohio State Medical Association agreed,
as part of the settlement, to make a $1 million grant to the geriatric medicine programs
at seven medical schools, to give the Ohio Attorney General the power to choose directors,
only four of which may be doctors, and to accept $56,000 it paid for the stock more than
30 years ago without interest in return for relinquishing control. Id.
206 Northern Pacific Ry. Co. v. United States, 356 U.S. 1, 5 (1958).
207 549 F.2d 626 (9th Cir. 1977), cert. denied, 434 U.S. 825 (1978). Another state court
case held that there was no tying agreement when a Blue Shield Plan required member
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group of Arizona dentists brought suit against the state dental association,
which required that its members also belong to the national dental associa-
tion. Such a stipulation has all the earmarks of a tie-in: the requirement of
the purchase of an unwanted product or service as a condition of purchase
of the desired item. The district court's dismissal of the action on professional
exemption and interstate commerce grounds was reversed on appeal, and
there has not yet been any decision by the lower court to which the case
was remanded for consideration of the merits.
United States Dental Institute v. American Association of Orthodontists0 8
typifies a possible trend in private antitrust actions in the health industry.
As such, it can be thought of as a potentially ominous sign or as an oppor-
tunity for righting wrongs, depending on one's perspective. In this case a
private, for-profit educational institution and a number of practicing
dentists brought suit against the American Association of Orthodontists, the
American Dental Association, and a number of officers of both associations
individually. The plaintiffs sought treble damages and injunctive relief under
Sections 1 and 2 of the Sherman Act. The Dental Institute offered ortho-
dontic courses and seminars to dentists in general practice so that they
could become qualified as dental specialists without returning to a dental
school for more traditional academic work. The Institute alleged that the
defendants conspired to restrain and destroy its business in order to restrict
the number of specialists and perpetuate the monopolistic position of special-
ists currently in practice.
The court's opinion on a motion to dismiss disposed of a number of
procedural defenses, including the failure to affect interstate commerce"'
and the claim that professionals were exempt from antitrust regulation. 1'
The court further refused to credit defendants' arguments "that they were
motivated only by a sense of duty to protect the general practitioner dentists
from substandard education and to protect the public from treatment by
less than qualified practitioners, 2.1 finding instead that the defendants'
physicians to participate in all its service programs rather than. those they chose. Connecticut
State Medical Soc'y v. Connecticut Medical Service, Inc., 29 Conn. Supp. 474, 293 A.2d
794 (1971). See also Bogus v. American Speech & Hearing Ass'n, 582 F.2d 277 (3d Cir.
1978) (Tie-in of certification with professional association membership alleged, dismissal
denied). Several cases have also recently held it permissible for a hospital to require an
attending physician to have malpractice insurance as a condition of securing or retaining
admitting privileges. See, e.g., Holmes v. Hoemako Hospital, 11 Ariz. 403, 573 P.2d 477
(1977). It is not known, however, whether or not such a requirement was challenged on
antitrust grounds as a tying agreement.
208396 F. Supp. 565 (N.D. 111. 1975).
209 Id. at 577.
210 Id. at 579.
211 Id. at 580. In this case the quality assurance defense failed to convince the court. On the
quality assurance defense, see note 153 and accompanying text supra.
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actions operated "on the business and commercial aspects of the dental
practice by preserving the orthodontists' special commercial interests." 1 '
On such a motion a court can neither evaluate the credibility of any
of the plaintiff's allegations nor know if the plaintiff can provide sufficient
evidence to support his claim on trial. Still, the court in United States Dental
Institute took the position, as an increasing number of other courts are doing,
that the evidence must be heard and weighed on the merits as in the trial
of any other issue involving commercial interests. On the merits, the restraints
imposed by professional associations, codes of ethics, and health care pro-
viders may be sustained due to the facts of the particular case, the needs of
the industry or, simply, on broader grounds of public policy. However,
they will be examined and tested by many of the usual and traditional
standards applicable to trade regulation.
CONCLUSION
What course can be counseled for those guiding craft afloat on this
rising tide of antitrust litigation? The same as for any business: seek counsel
before embarking on a new venture of any economic substance which
could, in any way, be deemed to violate the laws discussed above. In addi-
tion, existing arrangements and practices should also be reviewed.
From a broader social policy point of view there are likely to be
serious problems in the future as the enforcement policies of the federal
and state government trade regulation agencies or decisions in private
antitrust actions conflict with public health policy as administered by the
United States Department of Health, Education & Welfare (HEW) and
the corresponding state agencies.
Conflict between the federal antitrust agencies, themselves, on how
to regulate the health industry is not unknown. For example, the writer is
defending one of the peer review cases mentioned above21 and has had
occasion to speak with the FTC about the practice. In the eyes of the New
York Regional Office, peer review was viewed as a suspect activity because
of possible influence on prices. Shortly thereafter, the Antitrust Division
issued an opinion in response to an inquiry from a national association
giving a clean bill of health to the identical practice." ' HEW, also, some-
times appears to take divergent approaches to competition in the industry.
The policy to promote HMO's is premised on their proliferation with con-
212 Id. at 581. Compare with text accompanying note 79 supra. As in the Feminist and Gold-
farb cases, a claim of "good faith" or "quality assurance" is inconsistent with demonstrated
self-interest.
213 See text accompanying note 190 supra.
214 See note 189 supra.
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sequent competition between them and, hopefully, lower prices and higher
quality. However, a cornerstone of national public health policy, as embodied
in the National Health Planning and Resource Development Act of 1974.15
is limitation of growth.
It is hard to know how to navigate in these waters astir with the
treacherous cross-current of treble damage actions and lined with regulatory
reefs. A single encounter with one of these perils could spell the end of
even a substantial health facility. The dangers of losing a private action or
an enforcement action are obvious. However, with the disruption, uncertainty
and enormous defense costs of antitrust litigation, even a victory can be a
Pyrrhic one.
Guidance is clearly needed in this area. This may come out of the
joint hearings of the Senate Subcommittee on Health and the Sub-
committee on Antitrust and Monopolies both announced by Senator Edward M.
Kennedy who chaired both subcommittees. 16 Given the Senator's well known
and long time commitment to comprehensive national health insurance, his
interest is likely to be in the direction of an industry more closely regulated
by the federal government. While legislation purposed toward this end may
also include some express or implied relief from the antitrust laws, it may
not. One thing is certain, in order to preserve a viable health delivery
system, the incessant enactment of federal and state laws restricting the
competitive freedom of health providers cannot continue while the tempo
of antitrust enforcement increases. There must be relief in one direction or
the other.
215 42 U.S.C. § 300K (Supp. 1977). Indeed, current proposed amendments would even
extend the scope of the Act to include private physician's offices. However, these same
amendments would also exempt HMO's from the Act, thus tempering the apparent incon-
sistency referred to in the text.
216 See N.Y. Times, June 28, 1977 at p. 17, col. 6.
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